Cover
Cover - shares | 9 Months Ended | |
Sep. 30, 2023 | Nov. 06, 2023 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Sep. 30, 2023 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2023 | |
Current Fiscal Year End Date | --12-31 | |
Entity File Number | 001-32146 | |
Entity Registrant Name | DSS, INC. | |
Entity Central Index Key | 0000771999 | |
Entity Tax Identification Number | 16-1229730 | |
Entity Incorporation, State or Country Code | NY | |
Entity Address, Address Line One | 275 Wiregrass Pkwy | |
Entity Address, City or Town | West Henrietta | |
Entity Address, State or Province | NY | |
Entity Address, Postal Zip Code | 14586 | |
City Area Code | (585) | |
Local Phone Number | 325-3610 | |
Title of 12(b) Security | Common Stock, $0.02 par value per share | |
Trading Symbol | DSS | |
Security Exchange Name | NYSE | |
Entity Current Reporting Status | No | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 140,264,250 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Sep. 30, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 6,897,000 | $ 19,290,000 |
Accounts receivable, net | 3,136,000 | 7,564,000 |
Inventory | 3,930,000 | 7,721,000 |
Current portion of notes receivable | 9,225,000 | 11,719,000 |
Prepaid expenses and other current assets | 1,215,000 | 1,700,000 |
Total current assets | 24,403,000 | 47,994,000 |
Property, plant and equipment, net | 12,351,000 | 13,391,000 |
Investment in real estate, net | 53,482,000 | 55,029,000 |
Other investments | 1,163,000 | 1,534,000 |
Investment, equity method | 134,000 | 162,000 |
Marketable securities | 11,064,000 | 27,307,000 |
Notes receivable | 138,000 | 922,000 |
Other assets | 246,000 | 2,699,000 |
Right-of-use assets | 7,470,000 | 8,219,000 |
Goodwill | 57,880,000 | 60,919,000 |
Other intangible assets, net | 28,220,000 | 30,740,000 |
Total assets | 196,551,000 | 248,916,000 |
Current liabilities: | ||
Accounts payable | 2,924,000 | 5,914,000 |
Accrued expenses and deferred revenue | 2,701,000 | 19,341,000 |
Other current liabilities | 396,000 | 477,000 |
Current portion of lease liability | 813,000 | 796,000 |
Current portion of long-term debt, net | 46,638,000 | 47,161,000 |
Total current liabilities | 53,472,000 | 73,689,000 |
Long-term debt, net | 7,747,000 | 10,181,000 |
Long term lease liability | 7,040,000 | 7,820,000 |
Other long-term liabilities | 507,000 | 507,000 |
Deferred tax liability, net | 38,000 | 38,000 |
Commitments and contingencies (Note 12) | ||
Stockholders’ equity | ||
Common stock, $.02 par value; 200,000,000 shares authorized, 140,264,250 shares issued and outstanding (139,017,172 on December 31, 2022) | 2,804,000 | 2,779,000 |
Additional paid-in capital | 317,369,000 | 317,126,000 |
Accumulated deficit | (225,873,000) | (194,343,000) |
Total stockholders’ equity | 94,300,000 | 125,562,000 |
Non-controlling interest in subsidiaries | 33,447,000 | 31,119,000 |
Total stockholders’ equity | 127,747,000 | 156,681,000 |
Total liabilities and stockholders’ equity | $ 196,551,000 | $ 248,916,000 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares | Sep. 30, 2023 | Dec. 31, 2022 |
Statement of Financial Position [Abstract] | ||
Common stock, par value | $ 0.02 | $ 0.02 |
Common stock, shares authorized | 200,000,000 | 200,000,000 |
Common stock, shares issued | 140,264,250 | 139,017,172 |
Common stock, shares outstanding | 140,264,250 | 139,017,172 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Revenue: | ||||
Total revenue | $ 4,182,000 | $ 11,862,000 | $ 23,245,000 | $ 35,927,000 |
Costs and expenses: | ||||
Cost of revenue | 6,072,000 | 11,933,000 | 19,437,000 | 29,658,000 |
Selling, general and administrative (including stock-based compensation) | 3,213,000 | 14,677,000 | 21,036,000 | 40,316,000 |
Total costs and expenses | 9,285,000 | 26,610,000 | 40,473,000 | 69,974,000 |
Operating loss | (5,103,000) | (14,748,000) | (17,228,000) | (34,047,000) |
Other income (expense): | ||||
Interest income | 682,000 | 319,000 | 1,220,000 | 613,000 |
Dividend income | 12,000 | |||
Other income (expense) | (44,000) | 3,627,000 | 139,000 | 4,203,000 |
Interest expense | (51,000) | (42,000) | (438,000) | (100,000) |
Gain on extinguishment of debt | 110,000 | |||
Gain/(loss) on equity method investment | (6,000) | 344,000 | (28,000) | 134,000 |
Gain/(loss) on investments | 301,000 | (14,302,000) | (30,490,000) | (10,479,000) |
Provision for loan losses | (1,179,000) | (4,936,000) | ||
Loss on sale of assets | (1,281,000) | (1,281,000) | 405,000 | |
Loss from operations before income taxes | (6,681,000) | (24,802,000) | (53,030,000) | (39,161,000) |
Income tax benefit | (9,000) | |||
Net loss | (6,681,000) | (24,802,000) | (53,039,000) | (39,161,000) |
Loss from operations attributed to non-controlling interest | 2,339,000 | 4,587,000 | 2,736,000 | 6,247,000 |
Net loss attributable to common stockholders | $ (4,342,000) | $ (20,215,000) | $ (50,303,000) | $ (32,914,000) |
Loss per common share: | ||||
Basic | $ (0.03) | $ (0.15) | $ (0.36) | $ (0.32) |
Diluted | $ (0.03) | $ (0.15) | $ (0.36) | $ (0.32) |
Shares used in computing loss per common share: | ||||
Basic | 140,264,250 | 134,893,360 | 139,809,113 | 102,390,079 |
Diluted | 140,264,250 | 134,893,360 | 139,809,113 | 102,390,079 |
Printed Products [Member] | ||||
Revenue: | ||||
Total revenue | $ 3,315,000 | $ 5,032,000 | $ 12,976,000 | $ 12,650,000 |
Rental Income [Member] | ||||
Revenue: | ||||
Total revenue | 236,000 | 1,485,000 | 3,464,000 | 4,656,000 |
Management Fee Income [Member] | ||||
Revenue: | ||||
Total revenue | 38,000 | 38,000 | ||
Net Investment Income [Member] | ||||
Revenue: | ||||
Total revenue | 108,000 | 370,000 | 422,000 | 644,000 |
Commission Revenue [Member] | ||||
Revenue: | ||||
Total revenue | 295,000 | |||
Direct Marketing [Member] | ||||
Revenue: | ||||
Total revenue | $ 523,000 | $ 4,937,000 | $ 6,088,000 | $ 17,939,000 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022 | |
Cash flows from operating activities: | |||||
Net loss from continuing operations | $ (6,681,000) | $ (24,802,000) | $ (53,039,000) | $ (39,161,000) | |
Adjustments to reconcile net loss from continuing operations to net cash used by operating activities: | |||||
Depreciation and amortization | 4,150,000 | 9,351,000 | |||
Stock based compensation | 4,000 | ||||
Gain/loss on equity method investment | 28,000 | (134,000) | |||
Loss on investments | 30,490,000 | 10,479,000 | |||
Loss on allowance for obsolescence of inventory | 326,000 | ||||
Change in ROU assets | 749,000 | (7,961,000) | |||
Change in ROU liabilities | (763,000) | 8,297,000 | |||
Gain on extinguishment of debt | (110,000) | ||||
Loss/(gain) on sale of assets | 1,281,000 | (405,000) | |||
Impairment of notes receivable | 4,936,000 | 1,899,000 | |||
Decrease (increase) in assets: | |||||
Accounts receivable | 2,520,000 | (3,316,000) | |||
Inventory | 4,368,000 | (728,000) | |||
Prepaid expenses and other current assets | 323,000 | 568,000 | |||
Other assets | 2,448,000 | (904,000) | |||
Increase (decrease) in liabilities: | |||||
Accounts payable | (2,896,000) | 2,128,000 | |||
Accrued expenses | (15,549,000) | (3,205,000) | |||
Other liabilities | (81,000) | (379,000) | |||
Net cash used by operating activities | (21,035,000) | (23,251,000) | |||
Cash flows from investing activities: | |||||
Purchase of property, plant and equipment | (679,000) | (1,349,000) | |||
Purchase of real estate | (689,000) | ||||
Purchase of marketable securities | (14,254,000) | ||||
Disposal of property, plant and equipment | 215,000 | 2,557,000 | |||
Sale of marketable securities | 11,330,000 | ||||
Issuance of new notes receivable, net origination fees | (400,000) | (4,687,000) | |||
Payments received on notes receivable | 1,419,000 | 786,000 | |||
Purchase of intangible assets | (180,000) | ||||
Net cash provided (used) by investing activities | 11,885,000 | (17,816,000) | |||
Cash flows from financing activities: | |||||
Payments of long-term debt | (4,056,000) | (561,000) | |||
Borrowings of long-term debt | 813,000 | 6,360,000 | |||
Issuances of common stock, net of issuance costs | 1,518,000 | ||||
Net cash (used)provided by financing activities | (3,243,000) | 7,317,000 | |||
Net decrease in cash | (12,393,000) | (33,750,000) | |||
Cash and cash equivalents at beginning of period | 19,290,000 | 56,595,000 | $ 56,595,000 | ||
Cash and cash equivalents at end of period | $ 6,897,000 | $ 22,845,000 | $ 6,897,000 | $ 22,845,000 | $ 19,290,000 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) | Common Stock [Member] | Preferred Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Parent [Member] | Noncontrolling Interest [Member] | Total |
Beginning balance, value at Dec. 31, 2021 | $ 1,594,000 | $ 294,685,000 | $ (134,503,000) | $ 161,776,000 | $ 36,409,000 | $ 198,185,000 | |
Beginning balance, shares at Dec. 31, 2021 | 79,746,000 | ||||||
Issuance of common stock, net of expenses | $ 858,000 | 16,547,000 | 17,405,000 | 17,405,000 | |||
Issuance of common stock, net of expenses, shares | 47,924,000 | ||||||
Net loss | (32,914,000) | (32,914,000) | (6,247,000) | (39,161,000) | |||
Stock based payments | $ 327,000 | 5,893,000 | 6,220,000 | 6,220,000 | |||
Stock based payments, shares | 16,347,000 | ||||||
Ending balance, value at Sep. 30, 2022 | $ 2,779,000 | 317,125,000 | (167,417,000) | 152,487,000 | 30,162,000 | 182,649,000 | |
Ending balance, shares at Sep. 30, 2022 | 139,017,000 | ||||||
Beginning balance, value at Dec. 31, 2022 | $ 2,779,000 | 317,126,000 | (194,343,000) | 125,562,000 | 31,119,000 | 156,681,000 | |
Beginning balance, shares at Dec. 31, 2022 | 139,017,000 | ||||||
Issuance of common stock, net of expenses | $ 25,000 | 243,000 | 268,000 | 268,000 | |||
Issuance of common stock, net of expenses, shares | 1,247,000 | ||||||
Deconsolidation of Sharing Services | 18,773,000 | 18,773,000 | 5,064,000 | 23,837,000 | |||
Net loss | (50,303,000) | (50,303,000) | (2,736,000) | (53,039,000) | |||
Ending balance, value at Sep. 30, 2023 | $ 2,804,000 | $ 317,369,000 | $ (225,873,000) | $ 94,300,000 | $ 33,447,000 | $ 127,747,000 | |
Ending balance, shares at Sep. 30, 2023 | 140,264,000 |
Basis of Presentation and Signi
Basis of Presentation and Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of Presentation and Significant Accounting Policies | 1. Basis of Presentation and Significant Accounting Policies The Company, incorporated in the state of New York in May 1984 has conducted business in the name of Document Security Systems, Inc. On September 16, 2021, the board of directors approved an agreement and plan of merger with a wholly owned subsidiary, DSS, Inc. (a New York corporation, incorporated in August 2020), for the sole purpose of effecting a name change from Document Security Systems, Inc. to DSS, Inc. This change became effective on September 30, 2021. DSS, Inc. maintained the same trading symbol “DSS” and updated its CUSIP number to 26253C 102. DSS, Inc. (together with its consolidated subsidiaries, referred to herein as “DSS,” “we,” “us,” “our” or the “Company”) currently operates nine (9) distinct business lines with operations and locations around the globe. These business lines are: (1) Product Packaging, (2) Biotechnology, (3) Direct Marketing, (4) Commercial Lending, (5) Securities and Investment Management, (6) Alternative Trading (7) Digital Transformation, (8) Secure Living, and (9) Alternative Energy. Each of these business lines are in different stages of development, growth, and income generation. Our divisions, their business lines, subsidiaries, and operating territories: (1) Our Product Packaging line is led by Premier Packaging Corporation, Inc. (“Premier”), a New York corporation. Premier operates in the paper board and fiber based folding carton, consumer product packaging, and document security printing markets. It markets, manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex 3-dimensional direct mail solutions. Premier is currently located in its new facility in Rochester, NY, and primarily serves the US market. (2) The Biotechnology business line was created to invest in or acquire companies in the BioHealth and BioMedical fields, including businesses focused on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. This division is also targeting unmet, urgent medical needs, and is developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. (3) Direct Marketing, led by the holding corporation, Decentralized Sharing Systems, Inc. (“Decentralized”) provides services to assist companies in the emerging growth “Gig” business model of peer-to-peer decentralized sharing marketplaces. Direct specializes in marketing and distributing its products and services through its subsidiary and partner network, using the popular gig economic marketing strategy as a form of direct marketing. Direct Marketing’s products include, among other things, nutritional and personal care products sold throughout North America, Asia Pacific, Middle East, and Eastern Europe. (4) Our Commercial Lending business division, driven by American Pacific Bancorp (“APB”), is organized for the purposes of being a financial network holding company, focused on acquiring equity positions in (i) undervalued commercial bank(s), bank holding companies and nonbanking licensed financial companies operating in the United States, South East Asia, Taiwan, Japan and South Korea, and (ii) companies engaged in—nonbanking activities closely related to banking, including loan syndication services, mortgage banking, trust and escrow services, banking technology, loan servicing, equipment leasing, problem asset management, SPAC (special purpose acquisition company) consulting services, and advisory capital raising services. (5) Securities and Investment Management was established to develop and/or acquire assets in the securities trading or management arena, and to pursue, among other product and service lines, broker dealers, and mutual funds management. Also in this segment is the Company’s real estate investment trusts (“REIT”), organized for the purposes of acquiring hospitals and other acute or post-acute care centers from leading clinical operators with dominant market share in secondary and tertiary markets, and leasing each property to a single operator under a triple-net lease. the REIT was formed to originate, acquire, and lease a credit-centric portfolio of licensed medical real estate. (6) Alternative Trading was established to develop and/or acquire assets and investments in the securities trading and/or funds management arena. Alternative Trading, in partnership with recognized global leaders in alternative trading systems, intends to own and operate in the US a single or multiple vertical digital asset exchanges for securities, tokenized assets, utility tokens, and cryptocurrency via an alternative trading platform using blockchain technology. The scope of services within this section is planned to include asset issuance and allocation (securities and cryptocurrency), FPO, IPO, ITO, PPO, and UTO listings on a primary market(s), asset digitization/tokenization (securities, currency, and cryptocurrency), and the listing and trading of digital assets (securities and cryptocurrency) on a secondary market(s). (7) Digital Transformation was established to be a Preferred Technology Partner and Application Development Solution for mid cap brands in various industries including the direct selling and affiliate marketing sector. Digital improves marketing, communications and operations processes with custom software development and implementation. (8) The Secure Living division has developed a plan for fully sustainable, secure, connected, and healthy living communities with homes incorporating advanced technology, energy efficiency, and quality of life living environments both for new construction and renovations for single and multi-family residential housing. (9) The Alternative Energy group was established to help lead the Company’s future in the clean energy business that focuses on environmentally responsible and sustainable measures. Alset Energy, Inc, the holding company for this group, and its wholly owned subsidiary, Alset Solar, Inc., pursue utility-scale solar farms to serve US regional power grids and to provide underutilized properties with small microgrids for independent energy. On May 13, 2021, Sentinel Brokers, LLC. (“Sentinel LLC”), subsidiary of the Company entered into a stock purchase agreement (“Sentinel Agreement”) to acquire a 24.9 75 5 80.1 The accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments, unless otherwise indicated) necessary to present fairly our consolidated financial position as of September 30, 2023 and December 31, 2022, and the results of our consolidated operations for the interim periods presented. We follow the same accounting policies when preparing quarterly financial data as we use for preparing annual data. These statements should be read in conjunction with the consolidated financial statements and the notes included in our latest annual report on Form 10-K, and 10-K/A for the fiscal year ended December 31, 2022 (“Form 10-K”, “Form 10-K/A”), and our other reports on file with the Securities and Exchange Commission (the “SEC”). Principles of Consolidation Deconsolidation of Sharing Services Global Corporation - 280 7 81 s a result, SHRG, whose operations represented a significant portion of our Direct Marketing segment, was deconsolidated from our consolidated financial statements effective as of May 1, 2023 (the “Deconsolidation”). The consolidated statement of operations for the fiscal quarter ended September 30, 2023, therefore includes one month of activity related to SHRG prior to the Deconsolidation. Subsequent to April 30, 2023 the assets and liabilities of SHRG are no longer included within our consolidated balance sheets. Any discussions related to results, operations, and accounting policies associated with SHRG refer to the periods prior to the Deconsolidation. Upon Deconsolidation, we recognized a loss before income taxes of approximately $ 29,196,000 148,000 Reclassifications Use of Estimates Cash Equivalents Accounts/Rents Receivable At September 30, 2023, and December 31, 2022, the Company established a reserve for doubtful accounts of approximately $ 2,706,000 29,000 Notes receivable, unearned interest, and related recognition Investments Fair Value of Financial Instruments - ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the consolidated balance sheet of cash and cash equivalents, accounts receivable, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Marketable securities classify as a Level 1 fair value financial instrument. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do not reflect recent market conditions. The fair value of revolving credit lines notes payable and long-term debt approximates their carrying value as the stated or discounted rates of the debt reflect recent market conditions. The fair value of investments where the fair value is not considered readily determinable, are carried at cost. Inventory – Inventories consist primarily of paper, pre-printed security paper, paperboard, fully prepared packaging, air filtration systems, and health and beauty products which and are stated at the lower of cost or net realizable value on the first-in, first-out (“FIFO”) method. Packaging work-in-process and finished goods included the cost of materials, direct labor and overhead. At the closing of each reporting period, the Company evaluates its inventory in order to adjust the inventory balance for obsolete and slow-moving items. An allowance for obsolescence of approximately $ 57,000 742,000 Impairment of Long-Lived Assets and Goodwill Business Combinations - Business combinations and non-controlling interests are recorded in accordance with FASB ASC 805 Business Combinations. Under the guidance, the assets and liabilities of the acquired business are recorded at their fair values at the date of acquisition and all acquisition costs are expensed as incurred. The excess of the purchase price over the estimated fair values is recorded as goodwill. If the fair value of the assets acquired exceeds the purchase price and the liabilities assumed, then a gain on acquisition is recorded. The application of business combination accounting requires the use of significant estimates and assumptions. (Loss) Earnings Per Common Share 0 0 0 11,597 Concentration of Credit Risk - As of September 30, 2023, two customers accounted for approximately 21% and 7% of our consolidated revenue and these two customers approximately 32% and 15% of our consolidated trade accounts receivable balance. As of December 31, 2022, two customers accounted for approximately 14% and 6% of our consolidated revenue and these two customers approximately 36% and 17% of our consolidated trade accounts receivable balance. Income Taxes Allowance For Loans And Lease Losses ASU No.2016-13 – Credit Losses” Going Concern 6.9 Aside from its $ 6.9 11.1 6.3 55 40.2 The Company’s management intends to take actions necessary to continue as a going concern. Management’s plans concerning these matters include, among other things, continued growth among our operating segments, and tightly controlling operating costs and reducing spending growth rates wherever possible to return to profitability. In addition, the Company has taken steps, and will continue to take measures, to materially reduce the expenses and cash burn at all corporate and business line levels. At the Company’s current operating levels and capital usage, we believe that without any further acquisition or investments, our $ 6.9 11.1 6.3 |
Revenue
Revenue | 9 Months Ended |
Sep. 30, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Revenue | 2. Revenue The Company recognizes its products and services revenue based on when the title passes to the customer or when the service is completed and accepted by the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for shipped product or service provided. Sales and other taxes billed and collected from customers are excluded from revenue. The Company recognizes rental income associated with its REIT, net of amortization of favorable/unfavorable lease terms relative to market and includes rental abatements and contractual fixed increases attributable to operating leases, where collection has been considered probable, on a straight-line basis over the term of the related lease. The Company recognizes net investment income from its investment banking line of business as interest owed to the Company occurs. The Company generates revenue from its direct marketing line of business primarily through internet sales and recognizes revenue as items are shipped. As of September 30, 2023, the Company had no unsatisfied performance obligations for contracts with an original expected duration of greater than one year. Pursuant to Topic 606, the Company has applied the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations. The Company elected the practical expedient allowing it to not recognize as a contract asset the commission paid to its salesforce on the sale of its products as an incremental cost of obtaining a contract with a customer but rather recognize such commission as expense when incurred as the amortization period of the asset that the Company would have otherwise recognized is one year or less. Sales Commissions Sales commissions are expensed as incurred for contracts with an expected duration of one year or less. There were no sales commissions capitalized as of September 30, 2023. Shipping and Handling Costs Costs incurred by the Company related to shipping and handling are included in cost of products sold. Amounts charged to customers relating to these costs are reflected as revenue. See Note 15 for disaggregated revenue information. |
Inventory
Inventory | 9 Months Ended |
Sep. 30, 2023 | |
Inventory Disclosure [Abstract] | |
Inventory | 3. Inventory Inventory consisted of the following as of: Schedule of Inventory September 30, 2023 December 31, 2022 Finished Goods $ 2,894,000 $ 6,779,000 Work in Process 79,000 403,000 Raw Materials 1,014,000 1,281,000 Inventory Gross $ 3,987,000 $ 8,463,000 Less allowance for obsolescence (57,000 ) (742,000 ) Inventory Net $ 3,930,000 $ 7,721,000 |
Notes Receivable
Notes Receivable | 9 Months Ended |
Sep. 30, 2023 | |
Receivables [Abstract] | |
Notes Receivable | 4. Notes Receivable Note 1 On February 8, 2021, the Company entered into a convertible promissory note (“Note 1”) with Borrower 1, a company registered in Gibraltar. The Company loaned the principal sum of $ 800,000 4% Note 2 On May 14, 2021, DSS Pure Air, Inc. a subsidiary of the Company entered a convertible promissory note (“Note 2”) with Borrower 2, a company registered in the state of Texas. Note 3 has an aggregate principal balance up to $ 5,000,000 6.65% May 1, 2023 Note 2 contains an optional conversion clause that allows the Company to convert all, or a portion of all, into newly issued member units of Borrower 2 with the maximum principal amount equal to 18% of the total equity position of Borrower 2 at conversion 5,544,000 5,420,000 2,884,000 Note 3 On September 23, 2021, APB entered into refunding bond anticipatory note (“Note 3”) with Borrower 3, which operates as a conservation and reclamation district pursuant to Chapter 3891, Texas Special District Local Laws Code ; Chapter 375, Texas Local Government Code; and Chapter 49, Texas Water Code. The District Note was in the sum of $ 3,500,000 5.59 September 22, 2022 September 19, 2024 3,854,000 3,701,000 Note 4 On October 25, 2021, APB entered into a loan agreement (“Note 4”) with Borrower 4, a company registered in the state of Utah. Note 4 has an initial aggregate principal balance up to $ 1,000,000 3,000,000 8.0 October 25, 2022 This note contains an optional conversion feature allowing APB to convert the outstanding principal to a 10% membership interest. 884,000 Note 5 On May 14, 2021, APB extended the credit (“Note 5”) to an individual (“Borrower 5”) in the form of two promissory notes for $ 250,000 and $ 10,000 respectively, bearing interest at 12.5 %, with a maturity date of May 15, 2023 . This promissory note was secured by a deed of trust on a tract of land, which is approximately 315 acres, and located in Coke County, Texas. The outstanding principal and interest for both notes were paid in full during the third quarter of 2023. $ 252,000 and $ 9,000 are included in Note receivable at December 31, 2022. Note 6 On October 27, 2021, HWH World, Inc., a subsidiary of the Company entered a revolving loan commitment (“Note 6”) with Borrower 8, a company registered in Taiwan. The outstanding principal and interest at September 30, 2023 and December 31, 2022 is $ 0 and $ 63,000 , respectively, and was included in Notes receivable current portion. This note has been written-off during the third quarter 2023. Note 7 On December 28, 2021, APB entered into a promissory note (“Note 7”) with Borrower 7, a company registered in the state of California. Note 7 has a principal balance of $ 700,000 12.0 December 28, 2022 May 31, 2023 404,000 701,000 Note 8 On January 24, 2022, APB and Borrower 8 entered into a promissory note (“Note 8”) in the principal sum of $ 100,000 6 January 2024 100,000 106,000 Note 9 On March 2, 2022, APB and Borrower 9, a corporation organized under the laws of the Republic of Korea entered into a promissory note (“Note 9”). Under the terms of Note 9, APB at its discretion, may lend up to the principal sum of $ 893,000 8 March 2024 440,000 9,00 874,000 25,000 Note 10 On May 9, 2022, DSS PureAir and Borrower 2 entered into a promissory note (“Note 10”) in the principal sum of $ 210,000 10 February 9, 2023 224,000 213,000 Note 11 On August 29, 2022, DSS Financial Management Inc and Borrower 11 entered into a promissory note (“Note 11”) in the principal sum of $ 100,000 8 August 29, 2025 99,000 100,000 68,000 31,000 Note 12 On July 26, 2022, APB and Borrower 12 entered into a promissory note (“Note 12”) in the principal sum of $ 1,000,000 8 July 26, 2024 929,000 30,000 924,000 66,000 Note 13 On June 15, 2022, Decentralized and Borrower 13 entered into a convertible promissory note (“Note 13”) in the principal sum of $ 27,000,000 8 0.03 June 14, 2024 26,000 0.0001 1,000 Note 14 On February 19, 2021, Impact BioMedical, Inc, a subsidiary of the Company, entered into a promissory note (Note 14) with Borrower 14. The Company loaned the principal sum of $ 206,000 6.5 August 19, 2022 204,000 206,000 16,000 190,000 Note 15 On May 8, 2023, DSS Financial Management Inc and Borrower 15 entered into a promissory note (“Note 15 “) in the principal sum of $ 102,000 2 10.5 May 7, 2026 104,000 44,000 60,000 Note 16 On June 27, 2023, Decentralized and Borrower 16 entered into a convertible promissory note (“Note 16”) in the principal sum of $ 1,400,000 with a discount of $ 300,000 and interest rate of 10 % and maturity date of September, 1, 2024 . The outstanding principal, interest, and associated discount was fully reserved for as of September 30, 2023. Note 17 On March 31,2023, DSS Biohealth Security, Inc and Borrower 17 entered into a promissory note (“Note 17”) in the principal sum of $ 140,000 8.5 March 31, 2025 130,000 83,000 46,500 Note 18 On September 28, 2023, APB and Borrower 18 entered into a promissory note (“Note 18”) in the principal sum of $ 400,000 5 November 12, 2023 401,000 Note 19 On August 11, 2022, APB and Borrower 19 entered into a promissory note (“Note 19”) in the principal sum of $ 1,430,000 8 August 12, 2024 1,102,000 375,000 |
Financial Instruments
Financial Instruments | 9 Months Ended |
Sep. 30, 2023 | |
Investments, All Other Investments [Abstract] | |
Financial Instruments | 5. Financial Instruments Cash, Cash Equivalents, Restricted Cash and Marketable Securities The following tables show the Company’s cash, cash equivalents, restricted cash, and marketable securities by significant investment category as of September 30, 2023, and December 31, 2022: Schedule of Cash and Marketable Securities by Significant Investment Category 2023 Unrealized Gain/ Fair Cash and Cash Marketable Cost (Loss) Value Equivalents Securities Cash $ 6,827,000 $ - $ 6,827,000 $ 6,827,000 $ - Level 1 Money Market Funds 70,000 - 70,000 70,000 - Marketable Securities 19,103,000 (8,039,000 ) 11,064,000 - 11,064,000 Total $ 26,000,000 $ (8,039,000 ) $ 17,961,000 $ 6,897,000 $ 11,064,000 2022 Unrealized Gain/ Fair Cash and Cash Marketable Cost (Loss) Value Equivalents Securities Investments Cash $ 19,226,000 $ - $ 19,226,000 $ 19,226,000 $ - $ - Level 1 Money Market Funds 64,000 - 64,000 64,000 - - Marketable Securities 36,263,000 (3,659,000 ) 27,307,000 - 27,307,000 - Level 2 Warrants 3,318,000 - 140,000 - - 140,000 Convertible securities 1,023,000 - 39,000 - - 39,000 Total $ 59,894,000 $ (3,659,000 ) $ 46,776,000 $ 19,290,000 $ 27,307,000 $ 179,000 The Company typically invests with the primary objective of minimizing the potential risk of principal loss. The Company’s investment policy generally requires securities to be investment grade and limits the amount of credit exposure to any one issuer. Fair values were determined for each individual security in the investment portfolio. |
Provision for Credit Losses
Provision for Credit Losses | 9 Months Ended |
Sep. 30, 2023 | |
Provision For Credit Losses | |
Provision for Credit Losses | 6. Provision for Credit Losses Effective December 31, 2022, the Company adopted amended accounting guidance “ ASU No.2016-13 – Credit Losses” As of December 31, 2022, and September 30, 2023 we have reviewed the entire loan portfolio as well as all financial assets of the Company for the purpose of evaluating the loan portfolio and the loan balances, including a review of individual and collective portfolio loan quality, loan(s) performance, including past due status and covenant defaults, assessment of the ability of the borrower to repay the loan on the loan terms, whether any loans should be placed on nonaccrual or returned to accrual, any concentrations in any single borrower and/or industry that we might need to further manage, and if any specific or general loan loss reserve should be established for the entire loan portfolio or for any specific loan. We analyzed the loan loss reserve from three basis: general loan portfolio reserves; industry portfolio reserves, and specific loan loss reserves. For the three and nine months ended September 30, 2023, the Company recorded a Loan loss reserve of approximately $ 1,179,000 4,936,000 General Loan Portfolio Reserve - 145,000 199,000 Industry Portfolio Reserves - Specific Loan Reserves 884,000 27,831,000 2,884,000 1,291,000 1,477,000 |
Disposal of assets
Disposal of assets | 9 Months Ended |
Sep. 30, 2023 | |
Disposal Of Assets | |
Disposal of assets | 7. Disposal of assets On July 1 st 1,000 shares of common stock, representing all the issued and outstanding common stock shares of HWH World for the sum $ 706,000 representing the gross proceeds of the sale of HWH inventory less cost of goods sold. The parties involved amended the terms of this agreement during the third quarter of 2023 from that of equity transaction to the purchase of inventory and assumption of certain liabilities by SHRG. The amended agreement identified the purchase price approximating $ 758,000 698,000 59,000 the agreement includes payment of 1% royalty, starting November 1, 2023, being defined as 1% of the gross sale price of all Seller’s new products made and sold outside of existing inventory on the schedule, for a period ending October 31, 2033. 639,000 On July 1 st 100 259,000 617,000 |
Investments
Investments | 9 Months Ended |
Sep. 30, 2023 | |
Investments, All Other Investments [Abstract] | |
Investments | 8. Investments Alset International Limited related party The Company owns 127,179,291 4 3,726,000 3,319,000 407,000 1,539,000 West Park Capital, Inc. On December 30, 2020, the Company signed a binding letter of intent with West Park Capital, Inc (“West Park”) and TBD where the parties agreed to prepare a note and stock exchange agreement whereby DSS will assign the TBD Note to West Park and West Park shall issue to DSS a stock certificate reflecting 7.5 500,000 BMI Capital International LLC On September 10, 2020, the Company’s wholly owned subsidiary DSS Securities, Inc. entered into membership interest purchase agreement with BMI Financial Group, Inc. a Delaware corporation (“BMIF”) and BMI Capital International LLC, a Texas limited liability company (“BMIC”) whereas DSS Securities, Inc. purchased 14.9 100,000 10 100,000 24.9 20 6,000 28,000 BMIC is a broker-dealer registered with the Securities and Exchange Commission, is a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”), and is a member of the Securities Investor Protection Corporation (“SIPC”). The Company’s chairman of the board and another independent board member of the Company also have ownership interest in BMIC. BioMed Technologies Asia Pacific Holdings Limited On December 19, 2020, Impact BioMedical, a wholly owned subsidiary of the Company, entered into a subscription agreement (the “Subscription Agreement”) with BioMed Technologies Asia Pacific Holdings Limited (“BioMed”), a limited liability company incorporated in the British Virgin Islands, pursuant to which the Company agreed to purchase 525 4.99 632,000 Under the terms of the Distribution Agreement, the Company will have exclusive rights to distribute the products within the United States, Canada, Singapore, Malaysia, and South Korea and non-exclusive distribution rights in all other countries. In exchange, the Company agreed to certain obligations, including mutual marketing obligations to promote sales of the products. This agreement is for ten years with a one year auto-renewal feature. Vivacitas Oncology, Inc. On March 15, 2021, the Company, through one of its subsidiaries, entered into a Stock Purchase Agreement (the “Vivacitas Agreement #1”) with Vivacitas Oncology Inc. (“Vivacitas”), to purchase 500,000 1.00 1,500,000 1.00 1.00 500,000 2,480,000 2,480,000 250,000 On April 1, 2021, the Company entered into an additional stock purchase agreement with Vivacitas (“Vivacitas Agreement #2”), whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the value of $ 1.00 120,000 On July 22, 2021, the Company exercised 1,000,000 1,000,000 16 100 4,100,000 Stemtech Corporation (Sharing Services Global Corp) In September 2021, the Company’s former subsidiary SHRG, Stemtech Corporation (“Stemtech”) and Globe Net Wireless Corp. (“GNTW”) entered into a Securities Purchase Agreement (the “SPA”) pursuant to which SHRG invested $ 1.4 1.4 500,000 September 9, 2024 10 1.4 154,173 0 44,000 0 39,000 In September 2021, SHRG entered into a Membership Unit Purchase Agreement pursuant to which the SHRG acquired a 30.75 1,537,000 100 |
Acquisitions
Acquisitions | 9 Months Ended |
Sep. 30, 2023 | |
Business Combination and Asset Acquisition [Abstract] | |
Acquisitions | 9. Acquisitions Sentinel Brokers Company, Inc. On May 13, 2021, Sentinel Brokers, LLC. (“Sentinel LLC”), subsidiary of the Company entered into a stock purchase agreement (“Sentinel Agreement”) to acquire a 24.9 300,000 750,000 1,050,000 Investments—Equity Method and Joint Ventures 50.1 75 The following summary, prepared on a proforma basis, combines the consolidated results of operations of the Company with those of Sentinel Co as if the acquisition took place on January 1. The pro forma consolidated results include the impact of certain adjustments. Schedule of Business Acquisition, Pro Forma Information 2022 (unaudited) Revenue $ 49,076,804 Net loss $ (61,680,088 ) Basic loss per share $ (0.55 ) Diluted loss per share $ (0.55 ) We are currently in the process of completing the purchase price accounting and related allocations associated with the acquisition of Sentinel Co. Assets included in this acquisition are cash of $ 3,977,000 344,000 1,000 1,274,000 Sentinel is a broker-dealer operating primarily as a fiduciary intermediary, facilitating intuitional trading of municipal and corporate bonds as well as preferred stock, and is registered with the Securities and Exchange Commission, is a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”), and is a member of the Securities Investor Protection Corporation (“SIPC”). |
Short-Term and Long-Term Debt
Short-Term and Long-Term Debt | 9 Months Ended |
Sep. 30, 2023 | |
Debt Disclosure [Abstract] | |
Short-Term and Long-Term Debt | 10. Short-Term and Long-Term Debt DSS, Inc Promissory Notes - 200,000 8.0 5.00 200,000 On March 16, 2021, American Medical REIT, Inc. received loan proceeds in the amount of approximately $ 110,000 1 111,000 On May 20, 2021, Premier Packaging entered into master loan and security agreement (“BOA Note”) with Bank of America, N.A. (“BOA”) to secure financing approximating $ 3,710,000 3,053,000 3,406,000 4.63 491,000 2,562,000 On August 1, 2021, AMRE Shelton, LLC., (“AMRE Shelton”) a subsidiary of AMRE, entered into a loan agreement (“Shelton Agreement”) with Patriot Bank, N.A. (“Patriot Bank”) in an amount up to $ 6,155,000 5,105,000 4.25 The interest will be adjusted commencing on July 1, 2026 and continuing for the next succeeding 5-year period shall be determined one month prior to the change date and shall be an interest rate equal to two hundred fifty (250) basis points above the Federal Home Loan Bank Boston 5-Year/25-Year amortizing advance rate, but in no event less than 4.25% for the term of 120 months 2,829,000 4.25 40,000 4,640,000 1,600,000 325,000 585,000 3 4,652,000 102,000 4,590,000 56,000 On October 13, 2021, LVAM entered into loan agreement with BMIC (“BMIC Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 512,000 3,000,000 On October 13, 2021, LVAM entered into a loan agreement with Lee Wilson Tsz Kin (“Wilson Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 1,997,000 3,000,000 On November 2, 2021, AMRE LifeCare entered into a loan agreement (“LifeCare Agreement”) with Pinnacle Bank, (“Pinnacle Bank”) in the amount of $ 40,300,000 62,000,000 32,100,000 12,100,000 1,500,000 15,901,000 1 11 52,407,000 The LifeCare Agreement calls for the principal amount of the in equal, consecutive monthly installments based upon a twenty-five (25) year amortization of the original principal amount of the LifeCare Agreement at an initial rate of interest equal to the interest rate determined in accordance as of July 29, 2022 provided, however, such rate of interest shall not be less than 4.28 8.46 November 2, 2023 November 2, 2024 40,193,000 270,000 40,462,000 24,000 2,672,000 952,000 In November 2021, AMRE entered into a convertible promissory note (“Alset Note”) with Alset International Limited (“Alset International”), a related party, for the principal amount of $ 8,350,000 8 matures in December 2023 8,805,000 21,366,177 8,350,000 119,000 625,000 346,000 On March 17, 2022, AMRE Winter Haven, LLC (“AMRE Winter Haven”) and Pinnacle Bank (“Pinnacle”) entered into a term loan (“Pinnacle Loan”) whereas Pinnacle lent to AMRE Winter Haven the principal sum of $ 2,990,000 March 7, 2024 4,500,000 3,200,000 1,000,000 222,000 29,000 5 4,450,000 25 4.28 35,000 2,966,000 60,000 2,952,000 24,000 153,000 On March 30, 2023, Premier Packaging, a subsidiary of the Company entered into a loan and security agreement with Union Bank & Trust Company for the principal amount of $ 790,000 7.44 14,000 746,000 112,000 634,000 A summary of scheduled principal payments of long-term debt, not including revolving lines of credit, subsequent to September 30, 2023, are as follows: Schedule of Notes Payable and Long-term Debt Year Amount 2024 46,952,000 2025 859,000 2026 901,000 2027 947,000 2028 1,200,000 Thereafter 3,526,000 |
Lease Liability
Lease Liability | 9 Months Ended |
Sep. 30, 2023 | |
Lease Liability | |
Lease Liability | 11. Lease Liability The Company has operating leases predominantly for operating facilities. As of September 30, 2023, the remaining lease terms on our operating leases range from less than one to twelve years. Renewal options to extend our leases have not been exercised due to uncertainty. Termination options are not reasonably certain of exercise by the Company. There is no transfer of title or option to purchase the leased assets upon expiration. There are no residual value guarantees or material restrictive covenants. There are no significant finance leases as of September 30, 2023. Future minimum lease payments as of September 30, 2023, are as follows: Maturity of Lease Liability: Schedule of Future Minimum Lease Payments Totals 2024 1,275,000 2025 861,000 2026 839,000 2027 808,000 2028 824,000 After 4,916,000 Total lease payments 9,523,000 Less: Imputed Interest (1,670,000 ) Present value of remaining lease payments $ 7,853,000 Current $ 813,000 Noncurrent $ 7,040,000 Weighted-average remaining lease term (years) 13.3 Weighted-average discount rate 4.3 % In March of 2022, Premier Packaging began leasing its relocated manufacturing facilities to West Henrietta, New York. This lease contains an escalating payment clause, ranging from $ 61,000 78,000 319,000 948,000 |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 12. Commitments and Contingencies License Agreement In exchange, the Licensee shall pay the Company a royalty of 5.5% of net sales. Under the terms of the Equivir Agreement, the Company shall reimburse the Licensee for 50% of the development costs provided that the development costs shall not exceed $ 1,250,000 |
Stockholders_ Equity
Stockholders’ Equity | 9 Months Ended |
Sep. 30, 2023 | |
Equity [Abstract] | |
Stockholders’ Equity | 13. Stockholders’ Equity Equity transactions On February 28, 2022, DSS entered into an Amendment to Stock Purchase Agreement (the “Amendment”) with its shareholder Alset EHome International Inc. (“AEI”), pursuant to which the Company and AEI have agreed to amend certain terms of the Stock Purchase Agreement dated January 25, 2022 (the “SPA”). Pursuant to the SPA, AEI had agreed to purchase up to 44,619,423 0.3810 17,000,000 3,986,877 $1,519,000 On March 10, 2022, the Company issued 894,084 340,000 On May 5, 2022, the Company issued 63,205 29,000 On May 25, 2022, the Company issued 15,389,995 5,848,000 On May 17, 2022, the shareholders of the Company approved the issuance of up to 21,366,177 8,350,000 367,000 On May 17, 2022, the shareholders of the Company approved the acquisition of 62,122,908 17,570,948 0.41 On April 10, 2023, the Company issued 1,247,078 268,000 Stock-Based Compensation – The Company records stock-based payment expense related to options and warrants based on the grant date fair value in accordance with FASB ASC 718. Stock-based compensation includes expense charges for all stock-based awards to employees, directors, and consultants. Such awards include option grants, warrant grants, and restricted stock awards. During the nine months ended September 30, 2023, the Company did not have stock compensation associated with these items, and 5,333 options were forfeited. Impact BioMedical, Inc. Equity Transactions – On August 8, 2023 DSS BioHealth Securities, Inc., a wholly-owned subsidiary of the Company, and the sole shareholder of Impact BioMedical Inc. , distributed to the shareholders of DSS on record as of July 10, 2023 4 shares of Impact Bio’s stock for 1 share they owned of DSS stock. Each share of Impact BioMedical distributed as part of the distribution will not be eligible for resale until 180 days from the date Impact BioMedical’s initial public offering becomes effective under the Securities Act, subject to the discretion of the Company to lift the restriction sooner. On October 31, 2023, Impact BioMedical effected a reverse stock split of 1 for 55. 3,877,282,251 70,496,041 60,496,041 60,496,041 88 12 |
Supplemental Cash Flow Informat
Supplemental Cash Flow Information | 9 Months Ended |
Sep. 30, 2023 | |
Supplemental Cash Flow Elements [Abstract] | |
Supplemental Cash Flow Information | 14. Supplemental Cash Flow Information The following table summarizes supplemental cash flows for the nine-months ended September 30, 2023, and 2022: Schedule of Supplemental Cash Flow Information 2023 2022 Cash paid for interest $ 3,432,000 $ 1,907,000 Non-cash investing and financing activities: Notes receivable converted to equity investments $ - $ 1,940,000 Shares issued for acquisition of marketable security $ - $ 7,169,000 Shares issued for the acquisition of notes receivable $ - $ 8,717,000 Right of use asset addition $ - $ 9,895,000 Shares issued in lieu of bonus cash $ 268,000 $ 6,216,000 |
Segment Information
Segment Information | 9 Months Ended |
Sep. 30, 2023 | |
Segment Reporting [Abstract] | |
Segment Information | 15. Segment Information The Company’s nine businesses lines are organized, managed, and internally reported as five operating segments. One of these operating segments, Product Packaging, is the Company’s packaging and printing group. Product Packaging operates in the paper board folding carton, smart packaging, and document security printing markets. It markets, manufactures, and sells mailers, photo sleeves, sophisticated custom folding cartons, and complex 3-dimensional direct mail solutions. These products are designed to provide functionality and marketability while also providing counterfeit protection. A second, Biotechnology, invests in, or acquires companies in the biohealth and biomedical fields, including businesses focused on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. This division is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Biotechnology is also targeting unmet, urgent medical needs. A third operating segment, Securities, and Investment Management (“Securities”) was established to develop and/or acquire assets and investments in the securities trading and/or funds management arena. Further, Securities, in partnership with recognized global leaders in alternative trading systems, intends to own and operate in the US a single or multiple vertical digital asset exchanges for securities, tokenized assets, utility tokens, stable coins and cryptocurrency via a digital asset trading platform using blockchain technology. The scope of services within this section is planned to include asset issuance and allocation (securities and cryptocurrency), FPO, IPO, ITO, PPO, STO and UTO listings on a primary market(s), asset digitization/tokenization (securities, currency, and cryptocurrency), and the listing and trading of digital assets (securities and cryptocurrency) on a secondary market(s). Also in this segment is the Company’s real estate investment trust (“REIT”), organized for the purposes of acquiring hospitals and other acute or post-acute care centers from leading clinical operators with dominant market share in secondary and tertiary markets, and leasing each property to a single operator under a triple-net lease. the REIT was formed to originate, acquire, and lease a credit-centric portfolio of licensed medical real estate. The fourth segment, Direct, provides services to assist companies in the emerging growth gig business model of peer-to-peer decentralized sharing marketplaces. It specializes in marketing and distributing its products and services through its subsidiary and partner network, using the popular gig economic marketing strategy as a form of direct marketing. Direct marketing products include, among other things, nutritional and personal care products sold throughout North America, Asia Pacific and Eastern Europe (see Note 1, Deconsolidation of Sharing Services Global Corporation). The fifth business line, Commercial Banking, is organized for the purposes of being a financial network holding company, focused providing commercial loans and on acquiring equity positions in (i) undervalued commercial bank(s), bank holding companies and nonbanking licensed financial companies operating in the United States, South East Asia, Taiwan, Japan and South Korea, and (ii) companies engaged in—nonbanking activities closely related to banking, including loan syndication services, mortgage banking, trust and escrow services, banking technology, loan servicing, equipment leasing, problem asset management, SPAC (special purpose acquisition company) consulting, and advisory capital raising services. From this financial platform, the Company shall provide an integrated suite of financial services for businesses that shall include commercial business lines of credit, land development financing, inventory financing, third party loan servicing, and services that address the financial needs of the world Gig Economy. Approximate information concerning the Company’s operations by reportable segment for the three and nine months ended September 30, 2023 and 2022 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Schedule of Operations by Reportable Segment Three Months Ended Product Commercial Direct September 30, 2023 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 3,378,000 $ 108,000 $ 523,000 $ - $ 173,000 $ - $ 4,182,000 Interest expense 51,000 - - - - - 51,000 Interest income - - 660,000 6,000 16,000 - 682,000 Net Loss (income) from operations (579,000 ) (24,000 ) (1,010,000 ) (1,151,000 ) (2,166,000 ) (1,751,000 ) (6,681,000 ) Capital expenditures 67,000 - - - - - 67,000 Identifiable assets 21,554,000 39,446,000 7,102,000 49,816,000 69,498,000 9,135,000 196,551,000 Three Months Ended Product Commercial Direct September 30, 2022 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 4,707,000 $ 370,000 $ 4,956,000 $ - $ 1,646,000 $ 183,000 $ 11,862,000 Depreciation and amortization 168,000 - 41,000 278,000 2,423,000 17,000 2,927,000 Interest Expense 42,000 - 193,000 - 371,000 - 606,000 Interest income - - 3,000 94,000 79,000 143,000 319,000 Net income (loss) from operations (1,077,000 ) 221,000 (15,379,000 ) (909,000 ) (3,182,000 ) (4,476,000 ) (24,802,000 ) Capital expenditures 300,000 - 73,000 - - - 373,000 Identifiable assets 24,035,000 48,121,000 39,979,000 57,225,000 81,766,000 13,754,000 264,880,000 Nine Months Ended Product Commercial Direct September 30, 2023 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 13,038,000 $ 422,000 $ 6,088,000 $ - $ 3,697,000 $ - $ 23,245,000 Interest expense 137,000 - (6,000 ) - 307,000 - 438,000 Interest income - - 945,000 149,000 126,000 - 1,220,000 Net income (loss) from operations (88,000 ) (1,800,000 ) (32,272,000 ) (5,933,000 ) (8,606,000 ) (4,340,000 ) (53,039,000 ) Capital expenditures 596,000 - - 17,000 66,000 - 679,000 Identifiable assets 21,554,000 39,446,000 7,102,000 49,816,000 69,498,000 9,135,000 196,551,000 Nine Months Ended Product Commercial Direct September 30, 2022 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 11,876,000 $ 644,000 $ 18,000,000 $ 94,000 $ 4,817,000 $ 496,000 $ 35,927,000 Depreciation and Amortization 525,000 - 248,000 835,000 7,637,000 106,000 9,351,000 Interest expense 100,000 - 193,000 - 1,812,000 - 2,105,000 Stock based compensation 1,000 - - - - 3,000 4,000 Net income (loss) from operations (755,000 ) 638,000 (19,102,000 ) (2,198,000 ) (8,334,000 ) (9,410,000 ) (39,161,000 ) Capital expenditures 1,242,000 - 88,000 - 15,000 4,000 1,349,000 Identifiable assets 24,035,000 48,121,000 39,979,000 57,225,000 81,766,000 13,754,000 264,880,000 The following tables disaggregate our business segment revenues by major source: Printed Products Revenue Information: Schedule of Disaggregation of Revenue Three months ended September 30, 2023 Packaging Printing and Fabrication $ 3,293,000 Commercial and Security Printing 22,000 Total Printed Products $ 3,315,000 Three months ended September 30, 2022 Packaging Printing and Fabrication $ 4,888,000 Commercial and Security Printing 144,000 Total Printed Products $ 5,032,000 Nine months ended September 30, 2023 Packaging Printing and Fabrication $ 12,539,000 Commercial and Security Printing 347,000 Total Printed Products $ 12,976,000 Nine months ended September 30, 2022 Packaging Printing and Fabrication $ 12,357,000 Commercial and Security Printing 293,000 Total Printed Products $ 12,650,000 Direct Marketing Three months ended September 30, 2023 Direct Marketing Internet Sales $ 523,000 Total Direct Marketing $ 523,000 Three months ended September 30, 2022 Direct Marketing Internet Sales $ 4,937,000 Total Direct Marketing $ 4,937,000 Nine months ended September 30, 2023 Direct Marketing Internet Sales $ 6,088,000 Total Direct Marketing $ 6,088,000 Nine months ended September 30, 2022 Direct Marketing Internet Sales $ 17,939,000 Total Direct Marketing $ 17,939,000 Rental Income Three months ended September 30, 2023 Rental income $ 236,000 Total Rental Income $ 236,000 Three months ended September 30, 2022 Rental income $ 1,485,000 Total Rental Income $ 1,485,000 Nine months ended September 30, 2023 Rental income $ 3,464,000 Total Rental Income $ 3,464,000 Nine months ended September 30, 2022 Rental income $ 4,656,000 Total Rental Income $ 4,656,000 Net Investment Income Three months ended September 30, 2023 Net Investment Income $ 108,000 Total Investment Income $ 108,000 Three months ended September 30, 2022 Net Investment Income $ 370,000 Total Rental Income $ 370,000 Nine months ended September 30, 2023 Net investment income $ 422,000 Total Management fee income $ 422,000 Nine months ended September 30, 2022 Net Investment Income $ 644,000 Total Management fee income $ 644,000 Commission Income Three months ended September 30, 2023 Commission income $ - Total commission income $ - Three months ended September 30, 2022 Commission income $ - Total commission income $ - Nine months ended September 30, 2023 Commission income $ 295,000 Total commission income $ 295,000 Nine months ended September 30, 2022 Commission income $ - Total commission income $ - |
Related Party Transactions
Related Party Transactions | 9 Months Ended |
Sep. 30, 2023 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 16. Related Party Transactions The Company owns 127,179,291 4 3,726,000 3,319,000 281,000 75,000 On March 2, 2020, AMRE entered into a $ 200,000 8.0 5.00 200,000 On March 18, 2021, the Company entered into an agreement with Alset EHome International, Inc. (“Seller”) to acquire the Seller’s wholly owned subsidiary Impact Oncology PTE Ltd for the purchase price of $ 2,480,000 2,480,000 250,000 15.7 1,000,000 16 On October 13, 2021, LVAM entered into loan agreement with BMIC (“BMIC Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 512,000 3,000,000 On October 13, 2021, LVAM entered into a loan agreement with Lee Wilson Tsz Kin (“Wilson Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 1,997,000 3,000,000 In November 2021, AMRE entered into a convertible promissory note (“Alset Note”) with Alset International Limited (“Alset International”), a related party, for the principal amount of $ 8,350,000 8 matures in December 2023 8,805,000 21,366,177 8,350,000 119,000 625,000 346,000 On February 28, 2022, DSS entered into an Amendment to Stock Purchase Agreement (the “Amendment”) with its shareholder Alset EHome International Inc. (“AEI”), pursuant to which the Company and AEI have agreed to amend certain terms of the Stock Purchase Agreement dated January 25, 2022 (the “SPA”). Pursuant to the SPA, AEI had agreed to purchase up to 44,619,423 0.3810 17,000,000 3,986,877 1,519,000 In October 2017, Sharing Services issued a Convertible Promissory Note in the principal amount of $ 50,000 333,333 333,333 0.15 78,635.62 On May 17, 2022, the shareholders of the Company approved the acquisition of 62,122,908 17,570,948 On May 17, 2022, the shareholders of the Company approved the issuance of up to 21,366,177 8,350,000 367,000 |
Subsequent Events
Subsequent Events | 9 Months Ended |
Sep. 30, 2023 | |
Subsequent Events [Abstract] | |
Subsequent Events | 17. Subsequent Events The Company has evaluated all subsequent events and transactions through November 14, 2023, the date that the condensed consolidated financial statements were available to be issued and noted no subsequent events requiring financial statement recognition or disclosure other than what was identified below: On October 31, 2023, Impact BioMedical effected a reverse stock split of 1 for 55. 3,877,282,251 70,496,041 60,496,041 60,496,041 88 12 |
Basis of Presentation and Sig_2
Basis of Presentation and Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Principles of Consolidation | Principles of Consolidation Deconsolidation of Sharing Services Global Corporation - 280 7 81 s a result, SHRG, whose operations represented a significant portion of our Direct Marketing segment, was deconsolidated from our consolidated financial statements effective as of May 1, 2023 (the “Deconsolidation”). The consolidated statement of operations for the fiscal quarter ended September 30, 2023, therefore includes one month of activity related to SHRG prior to the Deconsolidation. Subsequent to April 30, 2023 the assets and liabilities of SHRG are no longer included within our consolidated balance sheets. Any discussions related to results, operations, and accounting policies associated with SHRG refer to the periods prior to the Deconsolidation. Upon Deconsolidation, we recognized a loss before income taxes of approximately $ 29,196,000 148,000 Reclassifications |
Use of Estimates | Use of Estimates |
Cash Equivalents | Cash Equivalents Accounts/Rents Receivable At September 30, 2023, and December 31, 2022, the Company established a reserve for doubtful accounts of approximately $ 2,706,000 29,000 |
Notes receivable, unearned interest, and related recognition | Notes receivable, unearned interest, and related recognition |
Investments | Investments |
Fair Value of Financial Instruments | Fair Value of Financial Instruments - ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the consolidated balance sheet of cash and cash equivalents, accounts receivable, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Marketable securities classify as a Level 1 fair value financial instrument. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do not reflect recent market conditions. The fair value of revolving credit lines notes payable and long-term debt approximates their carrying value as the stated or discounted rates of the debt reflect recent market conditions. The fair value of investments where the fair value is not considered readily determinable, are carried at cost. |
Inventory | Inventory – Inventories consist primarily of paper, pre-printed security paper, paperboard, fully prepared packaging, air filtration systems, and health and beauty products which and are stated at the lower of cost or net realizable value on the first-in, first-out (“FIFO”) method. Packaging work-in-process and finished goods included the cost of materials, direct labor and overhead. At the closing of each reporting period, the Company evaluates its inventory in order to adjust the inventory balance for obsolete and slow-moving items. An allowance for obsolescence of approximately $ 57,000 742,000 |
Impairment of Long-Lived Assets and Goodwill | Impairment of Long-Lived Assets and Goodwill |
Business Combinations | Business Combinations - Business combinations and non-controlling interests are recorded in accordance with FASB ASC 805 Business Combinations. Under the guidance, the assets and liabilities of the acquired business are recorded at their fair values at the date of acquisition and all acquisition costs are expensed as incurred. The excess of the purchase price over the estimated fair values is recorded as goodwill. If the fair value of the assets acquired exceeds the purchase price and the liabilities assumed, then a gain on acquisition is recorded. The application of business combination accounting requires the use of significant estimates and assumptions. |
(Loss) Earnings Per Common Share | (Loss) Earnings Per Common Share 0 0 0 11,597 |
Concentration of Credit Risk | Concentration of Credit Risk - As of September 30, 2023, two customers accounted for approximately 21% and 7% of our consolidated revenue and these two customers approximately 32% and 15% of our consolidated trade accounts receivable balance. As of December 31, 2022, two customers accounted for approximately 14% and 6% of our consolidated revenue and these two customers approximately 36% and 17% of our consolidated trade accounts receivable balance. |
Income Taxes | Income Taxes Allowance For Loans And Lease Losses ASU No.2016-13 – Credit Losses” Going Concern 6.9 Aside from its $ 6.9 11.1 6.3 55 40.2 The Company’s management intends to take actions necessary to continue as a going concern. Management’s plans concerning these matters include, among other things, continued growth among our operating segments, and tightly controlling operating costs and reducing spending growth rates wherever possible to return to profitability. In addition, the Company has taken steps, and will continue to take measures, to materially reduce the expenses and cash burn at all corporate and business line levels. At the Company’s current operating levels and capital usage, we believe that without any further acquisition or investments, our $ 6.9 11.1 6.3 |
Inventory (Tables)
Inventory (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventory | Inventory consisted of the following as of: Schedule of Inventory September 30, 2023 December 31, 2022 Finished Goods $ 2,894,000 $ 6,779,000 Work in Process 79,000 403,000 Raw Materials 1,014,000 1,281,000 Inventory Gross $ 3,987,000 $ 8,463,000 Less allowance for obsolescence (57,000 ) (742,000 ) Inventory Net $ 3,930,000 $ 7,721,000 |
Financial Instruments (Tables)
Financial Instruments (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Investments, All Other Investments [Abstract] | |
Schedule of Cash and Marketable Securities by Significant Investment Category | The following tables show the Company’s cash, cash equivalents, restricted cash, and marketable securities by significant investment category as of September 30, 2023, and December 31, 2022: Schedule of Cash and Marketable Securities by Significant Investment Category 2023 Unrealized Gain/ Fair Cash and Cash Marketable Cost (Loss) Value Equivalents Securities Cash $ 6,827,000 $ - $ 6,827,000 $ 6,827,000 $ - Level 1 Money Market Funds 70,000 - 70,000 70,000 - Marketable Securities 19,103,000 (8,039,000 ) 11,064,000 - 11,064,000 Total $ 26,000,000 $ (8,039,000 ) $ 17,961,000 $ 6,897,000 $ 11,064,000 2022 Unrealized Gain/ Fair Cash and Cash Marketable Cost (Loss) Value Equivalents Securities Investments Cash $ 19,226,000 $ - $ 19,226,000 $ 19,226,000 $ - $ - Level 1 Money Market Funds 64,000 - 64,000 64,000 - - Marketable Securities 36,263,000 (3,659,000 ) 27,307,000 - 27,307,000 - Level 2 Warrants 3,318,000 - 140,000 - - 140,000 Convertible securities 1,023,000 - 39,000 - - 39,000 Total $ 59,894,000 $ (3,659,000 ) $ 46,776,000 $ 19,290,000 $ 27,307,000 $ 179,000 |
Acquisitions (Tables)
Acquisitions (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Sentinel Brokers Company Inc [Member] | |
Business Acquisition [Line Items] | |
Schedule of Business Acquisition, Pro Forma Information | The following summary, prepared on a proforma basis, combines the consolidated results of operations of the Company with those of Sentinel Co as if the acquisition took place on January 1. The pro forma consolidated results include the impact of certain adjustments. Schedule of Business Acquisition, Pro Forma Information 2022 (unaudited) Revenue $ 49,076,804 Net loss $ (61,680,088 ) Basic loss per share $ (0.55 ) Diluted loss per share $ (0.55 ) |
Short-Term and Long-Term Debt (
Short-Term and Long-Term Debt (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Debt Disclosure [Abstract] | |
Schedule of Notes Payable and Long-term Debt | A summary of scheduled principal payments of long-term debt, not including revolving lines of credit, subsequent to September 30, 2023, are as follows: Schedule of Notes Payable and Long-term Debt Year Amount 2024 46,952,000 2025 859,000 2026 901,000 2027 947,000 2028 1,200,000 Thereafter 3,526,000 |
Lease Liability (Tables)
Lease Liability (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Lease Liability | |
Schedule of Future Minimum Lease Payments | Future minimum lease payments as of September 30, 2023, are as follows: Maturity of Lease Liability: Schedule of Future Minimum Lease Payments Totals 2024 1,275,000 2025 861,000 2026 839,000 2027 808,000 2028 824,000 After 4,916,000 Total lease payments 9,523,000 Less: Imputed Interest (1,670,000 ) Present value of remaining lease payments $ 7,853,000 Current $ 813,000 Noncurrent $ 7,040,000 Weighted-average remaining lease term (years) 13.3 Weighted-average discount rate 4.3 % |
Supplemental Cash Flow Inform_2
Supplemental Cash Flow Information (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Supplemental Cash Flow Elements [Abstract] | |
Schedule of Supplemental Cash Flow Information | The following table summarizes supplemental cash flows for the nine-months ended September 30, 2023, and 2022: Schedule of Supplemental Cash Flow Information 2023 2022 Cash paid for interest $ 3,432,000 $ 1,907,000 Non-cash investing and financing activities: Notes receivable converted to equity investments $ - $ 1,940,000 Shares issued for acquisition of marketable security $ - $ 7,169,000 Shares issued for the acquisition of notes receivable $ - $ 8,717,000 Right of use asset addition $ - $ 9,895,000 Shares issued in lieu of bonus cash $ 268,000 $ 6,216,000 |
Segment Information (Tables)
Segment Information (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Segment Reporting [Abstract] | |
Schedule of Operations by Reportable Segment | Approximate information concerning the Company’s operations by reportable segment for the three and nine months ended September 30, 2023 and 2022 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Schedule of Operations by Reportable Segment Three Months Ended Product Commercial Direct September 30, 2023 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 3,378,000 $ 108,000 $ 523,000 $ - $ 173,000 $ - $ 4,182,000 Interest expense 51,000 - - - - - 51,000 Interest income - - 660,000 6,000 16,000 - 682,000 Net Loss (income) from operations (579,000 ) (24,000 ) (1,010,000 ) (1,151,000 ) (2,166,000 ) (1,751,000 ) (6,681,000 ) Capital expenditures 67,000 - - - - - 67,000 Identifiable assets 21,554,000 39,446,000 7,102,000 49,816,000 69,498,000 9,135,000 196,551,000 Three Months Ended Product Commercial Direct September 30, 2022 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 4,707,000 $ 370,000 $ 4,956,000 $ - $ 1,646,000 $ 183,000 $ 11,862,000 Depreciation and amortization 168,000 - 41,000 278,000 2,423,000 17,000 2,927,000 Interest Expense 42,000 - 193,000 - 371,000 - 606,000 Interest income - - 3,000 94,000 79,000 143,000 319,000 Net income (loss) from operations (1,077,000 ) 221,000 (15,379,000 ) (909,000 ) (3,182,000 ) (4,476,000 ) (24,802,000 ) Capital expenditures 300,000 - 73,000 - - - 373,000 Identifiable assets 24,035,000 48,121,000 39,979,000 57,225,000 81,766,000 13,754,000 264,880,000 Nine Months Ended Product Commercial Direct September 30, 2023 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 13,038,000 $ 422,000 $ 6,088,000 $ - $ 3,697,000 $ - $ 23,245,000 Interest expense 137,000 - (6,000 ) - 307,000 - 438,000 Interest income - - 945,000 149,000 126,000 - 1,220,000 Net income (loss) from operations (88,000 ) (1,800,000 ) (32,272,000 ) (5,933,000 ) (8,606,000 ) (4,340,000 ) (53,039,000 ) Capital expenditures 596,000 - - 17,000 66,000 - 679,000 Identifiable assets 21,554,000 39,446,000 7,102,000 49,816,000 69,498,000 9,135,000 196,551,000 Nine Months Ended Product Commercial Direct September 30, 2022 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 11,876,000 $ 644,000 $ 18,000,000 $ 94,000 $ 4,817,000 $ 496,000 $ 35,927,000 Depreciation and Amortization 525,000 - 248,000 835,000 7,637,000 106,000 9,351,000 Interest expense 100,000 - 193,000 - 1,812,000 - 2,105,000 Stock based compensation 1,000 - - - - 3,000 4,000 Net income (loss) from operations (755,000 ) 638,000 (19,102,000 ) (2,198,000 ) (8,334,000 ) (9,410,000 ) (39,161,000 ) Capital expenditures 1,242,000 - 88,000 - 15,000 4,000 1,349,000 Identifiable assets 24,035,000 48,121,000 39,979,000 57,225,000 81,766,000 13,754,000 264,880,000 |
Schedule of Disaggregation of Revenue | Printed Products Revenue Information: Schedule of Disaggregation of Revenue Three months ended September 30, 2023 Packaging Printing and Fabrication $ 3,293,000 Commercial and Security Printing 22,000 Total Printed Products $ 3,315,000 Three months ended September 30, 2022 Packaging Printing and Fabrication $ 4,888,000 Commercial and Security Printing 144,000 Total Printed Products $ 5,032,000 Nine months ended September 30, 2023 Packaging Printing and Fabrication $ 12,539,000 Commercial and Security Printing 347,000 Total Printed Products $ 12,976,000 Nine months ended September 30, 2022 Packaging Printing and Fabrication $ 12,357,000 Commercial and Security Printing 293,000 Total Printed Products $ 12,650,000 Direct Marketing Three months ended September 30, 2023 Direct Marketing Internet Sales $ 523,000 Total Direct Marketing $ 523,000 Three months ended September 30, 2022 Direct Marketing Internet Sales $ 4,937,000 Total Direct Marketing $ 4,937,000 Nine months ended September 30, 2023 Direct Marketing Internet Sales $ 6,088,000 Total Direct Marketing $ 6,088,000 Nine months ended September 30, 2022 Direct Marketing Internet Sales $ 17,939,000 Total Direct Marketing $ 17,939,000 Rental Income Three months ended September 30, 2023 Rental income $ 236,000 Total Rental Income $ 236,000 Three months ended September 30, 2022 Rental income $ 1,485,000 Total Rental Income $ 1,485,000 Nine months ended September 30, 2023 Rental income $ 3,464,000 Total Rental Income $ 3,464,000 Nine months ended September 30, 2022 Rental income $ 4,656,000 Total Rental Income $ 4,656,000 Net Investment Income Three months ended September 30, 2023 Net Investment Income $ 108,000 Total Investment Income $ 108,000 Three months ended September 30, 2022 Net Investment Income $ 370,000 Total Rental Income $ 370,000 Nine months ended September 30, 2023 Net investment income $ 422,000 Total Management fee income $ 422,000 Nine months ended September 30, 2022 Net Investment Income $ 644,000 Total Management fee income $ 644,000 Commission Income Three months ended September 30, 2023 Commission income $ - Total commission income $ - Three months ended September 30, 2022 Commission income $ - Total commission income $ - Nine months ended September 30, 2023 Commission income $ 295,000 Total commission income $ 295,000 Nine months ended September 30, 2022 Commission income $ - Total commission income $ - |
Basis of Presentation and Sig_3
Basis of Presentation and Significant Accounting Policies (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||
May 04, 2023 | May 04, 2023 | Mar. 09, 2022 | Feb. 28, 2022 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2022 | May 31, 2023 | May 03, 2023 | May 13, 2021 | |
Product Information [Line Items] | |||||||||||||
Deconsolidation on loss before income taxes | $ 29,196,000 | ||||||||||||
Accounts Receivable, Allowance for Credit Loss | $ 2,706,000 | $ 29,000 | |||||||||||
Allowance for obsolescence | 57,000 | $ 742,000 | |||||||||||
Cash | 6,900,000 | ||||||||||||
Proceeds from marketable securities | 11,100,000 | ||||||||||||
Principal and interest on note receivable | 6,300,000 | ||||||||||||
Pinnacle Bank [Member] | |||||||||||||
Product Information [Line Items] | |||||||||||||
Notes Payable | $ 40,200,000 | ||||||||||||
Customer One [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | |||||||||||||
Product Information [Line Items] | |||||||||||||
Concentration Risk, Percentage | 21% | 14% | |||||||||||
Customer One [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member] | |||||||||||||
Product Information [Line Items] | |||||||||||||
Concentration Risk, Percentage | 32% | 36% | |||||||||||
Customer Two [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | |||||||||||||
Product Information [Line Items] | |||||||||||||
Concentration Risk, Percentage | 7% | 6% | |||||||||||
Customer Two [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member] | |||||||||||||
Product Information [Line Items] | |||||||||||||
Concentration Risk, Percentage | 15% | 17% | |||||||||||
Warrant [Member] | |||||||||||||
Product Information [Line Items] | |||||||||||||
Anti dilutive securities excluded from computation of EPS | 0 | 0 | 0 | 11,597 | |||||||||
Sharing Services Global Corp [Member] | |||||||||||||
Product Information [Line Items] | |||||||||||||
Number of shares issued | 280,000,000 | ||||||||||||
Ownership interest percentage | 7% | 7% | |||||||||||
Value of marketable securities | $ 148,000 | ||||||||||||
Sharing Services Global Corpo [Member] | |||||||||||||
Product Information [Line Items] | |||||||||||||
Percentage of issued and outstanding | 81% | ||||||||||||
Impac tBio Medical [Member] | |||||||||||||
Product Information [Line Items] | |||||||||||||
Subsidiary, Ownership Percentage, Parent | 5,500% | ||||||||||||
Sentinel Brokers LLC [Member] | |||||||||||||
Product Information [Line Items] | |||||||||||||
Equity position percentage | 75% | 80.10% | |||||||||||
Stock Purchase Agreement [Member] | |||||||||||||
Product Information [Line Items] | |||||||||||||
Number of shares issued | 3,986,877 | 44,619,423 | |||||||||||
Sentinel Brokers LLC [Member] | |||||||||||||
Product Information [Line Items] | |||||||||||||
Acquisition percentage | 5% | ||||||||||||
Sentinel Brokers LLC [Member] | Stock Purchase Agreement [Member] | |||||||||||||
Product Information [Line Items] | |||||||||||||
Acquisition percentage | 24.90% |
Schedule of Inventory (Details)
Schedule of Inventory (Details) - USD ($) | Sep. 30, 2023 | Dec. 31, 2022 |
Inventory Disclosure [Abstract] | ||
Finished Goods | $ 2,894,000 | $ 6,779,000 |
Work in Process | 79,000 | 403,000 |
Raw Materials | 1,014,000 | 1,281,000 |
Inventory Gross | 3,987,000 | 8,463,000 |
Less allowance for obsolescence | (57,000) | (742,000) |
Inventory Net | $ 3,930,000 | $ 7,721,000 |
Notes Receivable (Details Narra
Notes Receivable (Details Narrative) - USD ($) | 9 Months Ended | 12 Months Ended | |||||||||||||||||||||
Aug. 28, 2023 | Jun. 27, 2023 | May 08, 2023 | Mar. 31, 2023 | Dec. 29, 2022 | Aug. 29, 2022 | Jul. 26, 2022 | Jun. 15, 2022 | May 09, 2022 | Mar. 02, 2022 | Jan. 24, 2022 | Dec. 28, 2021 | Oct. 25, 2021 | Sep. 23, 2021 | May 14, 2021 | Feb. 19, 2021 | Sep. 30, 2023 | Dec. 31, 2022 | Sep. 28, 2023 | Aug. 31, 2023 | Sep. 30, 2022 | Aug. 11, 2022 | Feb. 08, 2021 | |
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Notes receivable current | $ 9,225,000 | $ 11,719,000 | |||||||||||||||||||||
Notes Payable | $ 138,000 | 922,000 | |||||||||||||||||||||
Redeemable preferred stoc, per share | $ 1,000 | ||||||||||||||||||||||
Long term debt current | $ 46,638,000 | 47,161,000 | |||||||||||||||||||||
Series D Preferred Stock [Member] | |||||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Debt exchanged for shares | 26,000 | ||||||||||||||||||||||
Preferred stock, par value | $ 0.0001 | ||||||||||||||||||||||
Note 1 [Member] | |||||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Debt instrument face amount | $ 800,000 | ||||||||||||||||||||||
Debt instrument interest rate | 4% | ||||||||||||||||||||||
Note 2 [Member] | |||||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Debt instrument face amount | $ 5,000,000 | ||||||||||||||||||||||
Debt instrument interest rate | 6.65% | ||||||||||||||||||||||
Debt instrument maturity date | May 01, 2023 | ||||||||||||||||||||||
Debt conversion description | Note 2 contains an optional conversion clause that allows the Company to convert all, or a portion of all, into newly issued member units of Borrower 2 with the maximum principal amount equal to 18% of the total equity position of Borrower 2 at conversion | ||||||||||||||||||||||
Notes receivable current | 5,544,000 | 5,420,000 | |||||||||||||||||||||
Principal and interest outstanding | 2,884,000 | ||||||||||||||||||||||
Note 3 [Member] | |||||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Debt instrument face amount | $ 3,500,000 | ||||||||||||||||||||||
Debt instrument interest rate | 5.59% | ||||||||||||||||||||||
Debt instrument maturity date | Sep. 22, 2022 | ||||||||||||||||||||||
Notes receivable current | 3,854,000 | 3,701,000 | |||||||||||||||||||||
Extended maturity date | Sep. 19, 2024 | ||||||||||||||||||||||
Note 4 [Member] | |||||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Debt instrument interest rate | 8% | ||||||||||||||||||||||
Debt instrument maturity date | Oct. 25, 2022 | ||||||||||||||||||||||
Notes receivable current | 884,000 | ||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 3,000,000 | ||||||||||||||||||||||
Debt description | This note contains an optional conversion feature allowing APB to convert the outstanding principal to a 10% membership interest. | ||||||||||||||||||||||
Note 4 [Member] | Maximum [Member] | |||||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Debt instrument face amount | $ 1,000,000 | ||||||||||||||||||||||
Note 5 [Member] | |||||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Debt instrument interest rate | 12.50% | ||||||||||||||||||||||
Debt instrument maturity date | May 15, 2023 | ||||||||||||||||||||||
Note 5 [Member] | Promissory Note One [Member] | |||||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Debt instrument face amount | $ 250,000 | ||||||||||||||||||||||
Notes Payable | 252,000 | ||||||||||||||||||||||
Note 5 [Member] | Promissory Note Two [Member] | |||||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Debt instrument face amount | $ 10,000 | ||||||||||||||||||||||
Notes Payable | 9,000 | ||||||||||||||||||||||
Note 6 [Member] | |||||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Notes receivable current | 0 | 63,000 | |||||||||||||||||||||
Note 7 [Member] | |||||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Debt instrument face amount | $ 700,000 | ||||||||||||||||||||||
Debt instrument interest rate | 12% | ||||||||||||||||||||||
Debt instrument maturity date | Dec. 28, 2022 | ||||||||||||||||||||||
Notes receivable current | 404,000 | 701,000 | |||||||||||||||||||||
Extended maturity date | May 31, 2023 | ||||||||||||||||||||||
Note 8 [Member] | |||||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Debt instrument face amount | $ 100,000 | ||||||||||||||||||||||
Debt instrument interest rate | 6% | ||||||||||||||||||||||
Notes Payable | 100,000 | 106,000 | |||||||||||||||||||||
Debt instrument, face amount | January 2024 | ||||||||||||||||||||||
Note 9 [Member] | |||||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Debt instrument face amount | $ 893,000 | ||||||||||||||||||||||
Debt instrument interest rate | 8% | ||||||||||||||||||||||
Debt instrument, face amount | March 2024 | ||||||||||||||||||||||
Notes and loans receivable gross current | 440,000 | ||||||||||||||||||||||
Unamortized origination fees | 9 | 25,000 | |||||||||||||||||||||
Notes payable | 874,000 | ||||||||||||||||||||||
Note 10 [Member] | |||||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Debt instrument face amount | $ 210,000 | ||||||||||||||||||||||
Debt instrument interest rate | 10% | ||||||||||||||||||||||
Debt instrument maturity date | Feb. 09, 2023 | ||||||||||||||||||||||
Notes receivable current | 224,000 | ||||||||||||||||||||||
Notes payable | 213,000 | ||||||||||||||||||||||
Note 11 [Member] | |||||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Debt instrument face amount | $ 100,000 | ||||||||||||||||||||||
Debt instrument interest rate | 8% | ||||||||||||||||||||||
Debt instrument maturity date | Aug. 29, 2025 | ||||||||||||||||||||||
Notes receivable current | 68,000 | ||||||||||||||||||||||
Notes Payable | 100,000 | ||||||||||||||||||||||
Notes payable | 99,000 | ||||||||||||||||||||||
Notes receivable | 31,000 | ||||||||||||||||||||||
Note 12 [Member] | |||||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Debt instrument face amount | $ 1,000,000 | ||||||||||||||||||||||
Debt instrument interest rate | 8% | ||||||||||||||||||||||
Debt instrument maturity date | Jul. 26, 2024 | ||||||||||||||||||||||
Notes and loans receivable gross current | 30,000 | ||||||||||||||||||||||
Unamortized origination fees | 66,000 | ||||||||||||||||||||||
Notes payable | 929,000 | 924,000 | |||||||||||||||||||||
Note 13 [Member] | |||||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Debt instrument face amount | $ 27,000,000 | ||||||||||||||||||||||
Debt instrument interest rate | 8% | ||||||||||||||||||||||
Debt instrument maturity date | Jun. 14, 2024 | ||||||||||||||||||||||
Conversion price | $ 0.03 | ||||||||||||||||||||||
Note 14 [Member] | |||||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Debt instrument face amount | $ 206,000 | ||||||||||||||||||||||
Debt instrument interest rate | 6.50% | ||||||||||||||||||||||
Debt instrument maturity date | Aug. 19, 2022 | ||||||||||||||||||||||
Notes and loans receivable gross current | 204,000 | ||||||||||||||||||||||
Notes payable | 16,000 | $ 206,000 | $ 190,000 | ||||||||||||||||||||
Note 15 [Member] | |||||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Debt instrument face amount | $ 102,000 | ||||||||||||||||||||||
Debt instrument interest rate | 2% | ||||||||||||||||||||||
Debt instrument maturity date | Sep. 01, 2024 | May 07, 2026 | |||||||||||||||||||||
Notes payable | $ 104,000 | ||||||||||||||||||||||
Effective rate percentage | 10.50% | ||||||||||||||||||||||
Long term debt current | $ 44,000 | ||||||||||||||||||||||
Long term debt | 60,000 | ||||||||||||||||||||||
Note Sixteen [Member] | |||||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Debt instrument face amount | $ 1,400,000 | ||||||||||||||||||||||
Debt instrument interest rate | 10% | ||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 300,000 | ||||||||||||||||||||||
Note 17 [Member] | |||||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Debt instrument face amount | $ 140,000 | ||||||||||||||||||||||
Debt instrument interest rate | 8.50% | ||||||||||||||||||||||
Debt instrument maturity date | Mar. 31, 2025 | ||||||||||||||||||||||
Notes payable | 130,000 | ||||||||||||||||||||||
Long term debt current | 83,000 | ||||||||||||||||||||||
Long term debt | 46,500 | ||||||||||||||||||||||
Note Eighteen [Member] | |||||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Debt instrument face amount | $ 400,000 | ||||||||||||||||||||||
Debt instrument interest rate | 500% | ||||||||||||||||||||||
Debt instrument maturity date | Nov. 12, 2023 | ||||||||||||||||||||||
Notes payable | 401,000 | ||||||||||||||||||||||
Note Nineteen [Member] | |||||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||||
Debt instrument face amount | $ 1,430,000 | ||||||||||||||||||||||
Debt instrument interest rate | 800% | ||||||||||||||||||||||
Debt instrument maturity date | Aug. 12, 2024 | ||||||||||||||||||||||
Notes and loans receivable gross current | $ 375,000 | ||||||||||||||||||||||
Notes payable | $ 1,102,000 |
Schedule of Cash and Marketable
Schedule of Cash and Marketable Securities by Significant Investment Category (Details) - USD ($) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2023 | Dec. 31, 2022 | |
Cash and Cash Equivalents [Line Items] | ||
Adjusted Cost | $ 26,000,000 | $ 59,894,000 |
Unrealized Gain/(Loss) | (8,039,000) | (3,659,000) |
Fair Value | 17,961,000 | 46,776,000 |
Cash and Cash Equivalents | 6,897,000 | 19,290,000 |
Current marketable securities | 11,064,000 | 27,307,000 |
Investments | 179,000 | |
Fair Value, Inputs, Level 2 [Member] | Convertible Securities [Member] | ||
Cash and Cash Equivalents [Line Items] | ||
Adjusted Cost | 1,023,000 | |
Unrealized Gain/(Loss) | ||
Fair Value | 39,000 | |
Cash and Cash Equivalents | ||
Current marketable securities | ||
Investments | 39,000 | |
Fair Value, Inputs, Level 2 [Member] | Warrant [Member] | ||
Cash and Cash Equivalents [Line Items] | ||
Adjusted Cost | 3,318,000 | |
Unrealized Gain/(Loss) | ||
Fair Value | 140,000 | |
Cash and Cash Equivalents | ||
Current marketable securities | ||
Investments | 140,000 | |
Cash [Member] | ||
Cash and Cash Equivalents [Line Items] | ||
Adjusted Cost | 6,827,000 | 19,226,000 |
Unrealized Gain/(Loss) | ||
Fair Value | 6,827,000 | 19,226,000 |
Cash and Cash Equivalents | 6,827,000 | 19,226,000 |
Current marketable securities | ||
Investments | ||
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Cash and Cash Equivalents [Line Items] | ||
Adjusted Cost | 70,000 | 64,000 |
Unrealized Gain/(Loss) | ||
Fair Value | 70,000 | 64,000 |
Cash and Cash Equivalents | 70,000 | 64,000 |
Current marketable securities | ||
Investments | ||
Marketable Securities [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Cash and Cash Equivalents [Line Items] | ||
Adjusted Cost | 19,103,000 | 36,263,000 |
Unrealized Gain/(Loss) | (8,039,000) | (3,659,000) |
Fair Value | 11,064,000 | 27,307,000 |
Cash and Cash Equivalents | ||
Current marketable securities | $ 11,064,000 | 27,307,000 |
Investments |
Provision for Credit Losses (De
Provision for Credit Losses (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended |
Sep. 30, 2023 | Sep. 30, 2023 | Dec. 31, 2022 | |
General Loan Portfolio Reserve [Member] | American Pacific Bancorp [Member] | |||
Financing Receivable, Past Due [Line Items] | |||
Portfolio reserve | $ 199,000 | $ 145,000 | |
Specific Loan Reserves [Member] | American Pacific Bancorp [Member] | Asili LLC [Member] | |||
Financing Receivable, Past Due [Line Items] | |||
Current nonaccrual loan balance | 884,000 | ||
Resvered principal amount | $ 27,831,000 | 27,831,000 | $ 27,831,000 |
Specific Loan Reserves [Member] | American Pacific Bancorp [Member] | Asili LLC [Member] | Borrower Thirteen [Member] | |||
Financing Receivable, Past Due [Line Items] | |||
Outstanding principal and interest | 2,884,000 | 2,884,000 | |
Specific Loan Reserves [Member] | American Pacific Bancorp [Member] | Asili LLC [Member] | Borrower Sixteen [Member] | |||
Financing Receivable, Past Due [Line Items] | |||
Outstanding principal and interest | 1,291,000 | 1,291,000 | |
Specific Loan Reserves [Member] | American Pacific Bancorp [Member] | Asili LLC [Member] | Borrower Nineteen [Member] | |||
Financing Receivable, Past Due [Line Items] | |||
Outstanding principal and interest | 1,477,000 | 1,477,000 | |
Loan [Member] | |||
Financing Receivable, Past Due [Line Items] | |||
Portfolio loan incurred | $ 1,179,000 | $ 4,936,000 |
Disposal of assets (Details Nar
Disposal of assets (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | |||
Jul. 01, 2023 | Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Proceeds from sale of inventory | $ 1,518,000 | ||||
Net loss | $ (4,342,000) | $ (20,215,000) | $ (50,303,000) | $ (32,914,000) | |
HWH World Inc [Member] | |||||
Equity percentage | 100% | ||||
Sharing Services Global Corporation [Member] | Amended Agreement [Member] | |||||
Proceeds from sale of inventory | $ 758,000 | ||||
Proceeds from sale of inventory | 698,000 | ||||
Liabilities assumed | 59,000 | ||||
Agreement description | the agreement includes payment of 1% royalty, starting November 1, 2023, being defined as 1% of the gross sale price of all Seller’s new products made and sold outside of existing inventory on the schedule, for a period ending October 31, 2033. | ||||
Net loss | $ 639,000 | ||||
HWH World Inc [Member] | |||||
Net loss | 6,170 | ||||
Purchase price consideration | $ 2,590 | ||||
HWH World Inc [Member] | Sharing Services Global Corporation [Member] | |||||
Sale of Stock, Number of Shares Issued in Transaction | 1,000 | ||||
Sale of Stock, Consideration Received Per Transaction | $ 706,000 |
Investments (Details Narrative)
Investments (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||
Jul. 22, 2021 | Apr. 01, 2021 | Mar. 18, 2021 | Mar. 15, 2021 | Dec. 30, 2020 | Dec. 19, 2020 | Sep. 10, 2020 | Sep. 30, 2021 | Sep. 30, 2023 | Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2022 | Mar. 31, 2022 | |
Unrealized gain loss on investments | $ (8,039,000) | $ (3,659,000) | ||||||||||||
Investments | $ 179,000 | |||||||||||||
Issuance of common stock, net of expenses | 268,000 | $ 17,405,000 | ||||||||||||
Proceeds from Issuance of common stock | 1,518,000 | |||||||||||||
Vivacitas Agreement [Member] | ||||||||||||||
Stock options exercised | 1,000,000 | |||||||||||||
Stock options exercised price | $ 1,000,000 | |||||||||||||
Investment ownership percentage | 100% | 100% | ||||||||||||
Investment owned at cost | $ 4,100,000 | |||||||||||||
Common Stock [Member] | ||||||||||||||
Issuance of common stock, net of expenses | $ 25,000 | $ 858,000 | ||||||||||||
Issuance of common stock, net of expenses, shares | 1,247,000 | 47,924,000 | ||||||||||||
BMI Capital International LLC [Member] | ||||||||||||||
Issuance of common stock, net of expenses | $ 100,000 | |||||||||||||
Investments equity method | $ 6,000 | $ 28,000 | ||||||||||||
Impact Oncology PTE Ltd. [Member] | ||||||||||||||
Owners shares | 2,480,000 | |||||||||||||
Options to purchase additional shares | 250,000 | |||||||||||||
Business combination consideration transferred | $ 2,480,000 | |||||||||||||
Stemtech Corporation [Member] | Securities Purchase Agreement [Member] | ||||||||||||||
Investments | $ 1,400,000 | $ 1,400,000 | ||||||||||||
Business combination consideration transferred | 1,400,000 | |||||||||||||
Convertible promissory note | $ 1,400,000 | 1,400,000 | ||||||||||||
Origination fee | $ 500,000 | |||||||||||||
Maturity date | Sep. 09, 2024 | |||||||||||||
Interest rate | 10% | 10% | ||||||||||||
Stockholders equity | 154,173 | |||||||||||||
Warrant outstanding | 0 | 0 | 0 | |||||||||||
Note payable | $ 44,000 | $ 44,000 | $ 39,000 | |||||||||||
DSS Securities, Inc. [Member] | ||||||||||||||
Equity method investment ownership percentage | 14.90% | |||||||||||||
BMI Capital International LLC [Member] | ||||||||||||||
Equity method investment ownership percentage | 24.90% | |||||||||||||
BMI Capital International LLC [Member] | Minimum [Member] | ||||||||||||||
Equity method investment ownership percentage | 20% | |||||||||||||
Bio Med Technologies Asia Pacific Holdings Limited [Member] | ||||||||||||||
Equity method investment ownership percentage | 4.99% | |||||||||||||
Issuance of common stock, net of expenses | $ 632,000 | |||||||||||||
Issuance of common stock, net of expenses, shares | 525 | |||||||||||||
Vivacitas Oncology Inc [Member] | Vivacitas Agreement [Member] | ||||||||||||||
Equity method investment ownership percentage | 16% | |||||||||||||
Moji Life LLC [Member] | Membership Unit Purchase Agreement [Member] | ||||||||||||||
Equity method investment ownership percentage | 30.75% | 30.75% | ||||||||||||
Payments to acquire equity method investments | $ 1,537,000 | |||||||||||||
Alset International Limited [Member] | ||||||||||||||
Owners shares | 127,179,291 | 127,179,291 | 127,179,291 | |||||||||||
Outstanding share percentage | 4% | |||||||||||||
Marketable securities | $ 3,726,000 | $ 3,726,000 | $ 3,319,000 | |||||||||||
Unrealized gain loss on investments | 281,000 | |||||||||||||
Alset International Limited [Member] | Executive Director And Chief Executive Officer [Member]. | ||||||||||||||
Unrealized gain loss on investments | 407,000 | $ 1,539,000 | ||||||||||||
West Park Capital Inc [Member] | ||||||||||||||
Debt instrument convertible threshold percentage of stock price trigger | 7.50% | |||||||||||||
Investments | $ 500,000 | $ 500,000 | $ 500,000 | |||||||||||
DSS Securities, Inc. [Member] | ||||||||||||||
Issuance of common stock, net of expenses | $ 100,000 | |||||||||||||
Outstanding membership interest | 10% | |||||||||||||
Vivacitas Oncology Inc [Member] | ||||||||||||||
Options to purchase additional shares | 1,500,000 | |||||||||||||
Shares issued, price per share | $ 1 | |||||||||||||
Additional price per share | $ 1 | |||||||||||||
Proceeds from Issuance of common stock | $ 500,000 | |||||||||||||
Business combination consideration transferred | $ 120,000 | |||||||||||||
Sale of stock, description | the Company entered into an additional stock purchase agreement with Vivacitas (“Vivacitas Agreement #2”), whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the value of $1.00 per share shall be $120,000 to be paid in twelve (12) equal monthly installments for the period between April 1, 2021 and March 31, 2022 | |||||||||||||
Share Price | $ 1 | |||||||||||||
Vivacitas Oncology Inc [Member] | Common Stock [Member] | ||||||||||||||
Options to purchase additional shares | 500,000 |
Schedule of Business Acquisitio
Schedule of Business Acquisition, Pro Forma Information (Details) | 12 Months Ended |
Dec. 31, 2022 USD ($) $ / shares | |
Business Combination and Asset Acquisition [Abstract] | |
Revenue | $ | $ 49,076,804 |
Net loss | $ | $ (61,680,088) |
Basic loss per share | $ / shares | $ (0.55) |
Diluted loss per share | $ / shares | $ (0.55) |
Acquisitions (Details Narrative
Acquisitions (Details Narrative) - USD ($) | Sep. 30, 2021 | May 13, 2021 | Sep. 30, 2023 | Dec. 31, 2022 |
Business Acquisition [Line Items] | ||||
Investments | $ 179,000 | |||
Goodwill | $ 57,880,000 | 60,919,000 | ||
Sentinel Brokers Company Inc [Member] | ||||
Business Acquisition [Line Items] | ||||
Purchae price | $ 300,000 | |||
Contribution of capital | $ 750,000 | |||
Investments | $ 1,050,000 | |||
Sentinel Brokers Company Inc [Member] | Common Class A [Member] | ||||
Business Acquisition [Line Items] | ||||
Percentage of outstanding common stock | 50.10% | |||
American Pacific Bancorp [Member] | ||||
Business Acquisition [Line Items] | ||||
Assets acquisition for cash | 3,977,000 | |||
Assets receivables | 344,000 | |||
Fixed assets | 1,000 | |||
Goodwill | $ 1,274,000 | |||
Sentinel Brokers Company Inc [Member] | ||||
Business Acquisition [Line Items] | ||||
Equity position percentage | 24.90% | 75% |
Schedule of Notes Payable and L
Schedule of Notes Payable and Long-term Debt (Details) | Sep. 30, 2023 USD ($) |
Debt Disclosure [Abstract] | |
2024 | $ 46,952,000 |
2025 | 859,000 |
2026 | 901,000 |
2027 | 947,000 |
2028 | 1,200,000 |
Thereafter | $ 3,526,000 |
Short-Term and Long-Term Debt_2
Short-Term and Long-Term Debt (Details Narrative) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||||||
May 17, 2022 USD ($) shares | Mar. 17, 2022 USD ($) | Nov. 02, 2021 USD ($) | Oct. 13, 2021 USD ($) | Oct. 13, 2021 USD ($) | Aug. 01, 2021 USD ($) ft² | Mar. 16, 2021 USD ($) | Nov. 30, 2021 USD ($) | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Dec. 31, 2022 USD ($) | Mar. 30, 2023 USD ($) | Jul. 29, 2022 | Dec. 31, 2021 USD ($) | May 20, 2021 USD ($) | Mar. 02, 2020 USD ($) $ / shares | |
Short-Term Debt [Line Items] | ||||||||||||||||||
Long term debt current | $ 46,638,000 | $ 46,638,000 | $ 47,161,000 | |||||||||||||||
Payments to acquire assets | 679,000 | $ 1,349,000 | ||||||||||||||||
Payments to intangible assets | 180,000 | |||||||||||||||||
Interest expense | 51,000 | $ 42,000 | 438,000 | $ 100,000 | ||||||||||||||
BMIC Loan [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Debt instrument, face amount | $ 3,000,000 | $ 3,000,000 | 512,000 | 512,000 | 3,000,000 | |||||||||||||
Maturity date | Oct. 12, 2022 | Oct. 12, 2022 | ||||||||||||||||
Wilson Loan [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Debt instrument, face amount | $ 3,000,000 | $ 3,000,000 | 1,997,000 | 1,997,000 | 3,000,000 | |||||||||||||
Maturity date | Oct. 12, 2022 | Oct. 12, 2022 | ||||||||||||||||
Security Agreement [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Debt instrument, face amount | 746,000 | 746,000 | $ 790,000 | |||||||||||||||
Principal interest percentage | 7.44% | |||||||||||||||||
Long term debt | 634,000 | 634,000 | ||||||||||||||||
Long term debt current | 112,000 | 112,000 | ||||||||||||||||
Interest Expense, Debt | 14,000 | |||||||||||||||||
American Medical REIT Inc. [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Debt instrument, face amount | $ 8,350,000 | |||||||||||||||||
Principal interest percentage | 1% | |||||||||||||||||
Proceeds from Paycheck Protection Program | $ 110,000 | |||||||||||||||||
Long term debt | $ 111,000 | |||||||||||||||||
Premier Packaging Bank Of America NA [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Debt instrument, face amount | 3,053,000 | 3,053,000 | $ 3,406,000 | |||||||||||||||
Principal interest percentage | 4.63% | |||||||||||||||||
Long term debt | 2,562,000 | 2,562,000 | ||||||||||||||||
Debt Financing Amount | $ 3,710,000 | |||||||||||||||||
Long term debt current | 491,000 | 491,000 | ||||||||||||||||
AMRE Shelton LLC [Member] | Loan Agreement [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Debt instrument, face amount | $ 6,155,000 | |||||||||||||||||
Principal interest percentage | 4.25% | |||||||||||||||||
Long term debt | 4,590,000 | 4,590,000 | ||||||||||||||||
Long term debt current | $ 5,105,000 | 102,000 | 102,000 | |||||||||||||||
Debt instrument description | The interest will be adjusted commencing on July 1, 2026 and continuing for the next succeeding 5-year period shall be determined one month prior to the change date and shall be an interest rate equal to two hundred fifty (250) basis points above the Federal Home Loan Bank Boston 5-Year/25-Year amortizing advance rate, but in no event less than 4.25% for the term of 120 months | |||||||||||||||||
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid | $ 2,829,000 | |||||||||||||||||
Debt effective interest rate percentage | 425% | |||||||||||||||||
Area of land | ft² | 40,000 | |||||||||||||||||
Payments to acquire assets | 4,652,000 | |||||||||||||||||
Payments to intangible assets | $ 585,000 | |||||||||||||||||
Debt issuance costs | 56,000 | 56,000 | ||||||||||||||||
AMRE Shelton LLC [Member] | Loan Agreement [Member] | Facility [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Payments to acquire assets | 4,640,000 | |||||||||||||||||
AMRE Shelton LLC [Member] | Loan Agreement [Member] | Land [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Payments to acquire assets | 1,600,000 | |||||||||||||||||
AMRE Shelton LLC [Member] | Loan Agreement [Member] | Tenant Improvements [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Payments to acquire assets | $ 325,000 | |||||||||||||||||
AMRE Shelton LLC [Member] | Loan Agreement [Member] | Other Intangible Assets [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Estimated useful life | 3 years | |||||||||||||||||
Pinnacle Bank [Member] | LifeCare Agreement [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Debt instrument, face amount | $ 40,300,000 | 40,462,000 | 40,462,000 | $ 40,193,000 | ||||||||||||||
Debt instrument description | The LifeCare Agreement calls for the principal amount of the in equal, consecutive monthly installments based upon a twenty-five (25) year amortization of the original principal amount of the LifeCare Agreement at an initial rate of interest equal to the interest rate determined in accordance as of July 29, 2022 provided, however, such rate of interest shall not be less than 4.28%, with the first such installment being payable on August 29, 2022 and subsequent installments being payable on the first day of each succeeding month thereafter until the maturity date, at which time any outstanding principal and interest is due in full | |||||||||||||||||
Debt effective interest rate percentage | 8.46% | 4.28% | ||||||||||||||||
Payments to acquire assets | $ 52,407,000 | |||||||||||||||||
Payments to intangible assets | $ 15,901,000 | |||||||||||||||||
Debt issuance costs | 24,000 | 24,000 | 270,000 | |||||||||||||||
Maturity date | Nov. 02, 2023 | |||||||||||||||||
Purchase price | $ 62,000,000 | |||||||||||||||||
Interest expense | 2,672,000 | 952,000 | ||||||||||||||||
Pinnacle Bank [Member] | LifeCare Agreement [Member] | Extended Maturity [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Maturity date | Nov. 02, 2024 | |||||||||||||||||
Pinnacle Bank [Member] | LifeCare Agreement [Member] | Minimum [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Estimated useful life | 1 year | |||||||||||||||||
Pinnacle Bank [Member] | LifeCare Agreement [Member] | Maximum [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Estimated useful life | 11 years | |||||||||||||||||
Pinnacle Bank [Member] | LifeCare Agreement [Member] | Facility [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Payments to acquire assets | $ 32,100,000 | |||||||||||||||||
Pinnacle Bank [Member] | LifeCare Agreement [Member] | Land [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Payments to acquire assets | 12,100,000 | |||||||||||||||||
Pinnacle Bank [Member] | LifeCare Agreement [Member] | Site Improvements [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Payments to acquire assets | $ 1,500,000 | |||||||||||||||||
Unsecured Promissory Note [Member] | American Medical REIT Inc. [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Debt instrument, face amount | $ 200,000 | |||||||||||||||||
Principal interest percentage | 8% | |||||||||||||||||
Class of warrant exercise price per share | $ / shares | $ 5 | |||||||||||||||||
Warrants and rights outstanding | $ 200,000 | |||||||||||||||||
Alset Note [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Debt instrument, face amount | $ 8,350,000 | $ 8,350,000 | 8,350,000 | |||||||||||||||
Principal interest percentage | 8% | |||||||||||||||||
Long term debt | $ 8,805,000 | 8,805,000 | ||||||||||||||||
Interest expense | 625,000 | 346,000 | ||||||||||||||||
Maturity date description | matures in December 2023 | |||||||||||||||||
Shares issued for convertible debt | shares | 21,366,177 | |||||||||||||||||
Accrued unpaid interest | $ 119,000 | 119,000 | ||||||||||||||||
Pinnacle Loan [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Debt instrument, face amount | $ 2,990,000 | 35,000 | 35,000 | 60,000 | ||||||||||||||
Principal interest percentage | 4.28% | |||||||||||||||||
Payments to acquire assets | 4,450,000 | |||||||||||||||||
Payments to intangible assets | $ 29,000 | |||||||||||||||||
Estimated useful life | 5 years | |||||||||||||||||
Debt issuance costs | $ 2,966,000 | 2,966,000 | 2,952,000 | |||||||||||||||
Maturity date | Mar. 07, 2024 | |||||||||||||||||
Purchase price | $ 4,500,000 | |||||||||||||||||
Interest expense | $ 24,000 | $ 153,000 | ||||||||||||||||
Debt instrument term | 25 years | |||||||||||||||||
Pinnacle Loan [Member] | Facility [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Payments to acquire assets | $ 3,200,000 | |||||||||||||||||
Pinnacle Loan [Member] | Land [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Payments to acquire assets | 1,000,000 | |||||||||||||||||
Pinnacle Loan [Member] | Site and Tenant Improvements [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Payments to acquire assets | $ 222,000 |
Schedule of Future Minimum Leas
Schedule of Future Minimum Lease Payments (Details) - USD ($) | Sep. 30, 2023 | Dec. 31, 2022 |
Lease Liability | ||
2024 | $ 1,275,000 | |
2025 | 861,000 | |
2026 | 839,000 | |
2027 | 808,000 | |
2028 | 824,000 | |
After | 4,916,000 | |
Total lease payments | 9,523,000 | |
Less: Imputed Interest | (1,670,000) | |
Present value of remaining lease payments | 7,853,000 | |
Current | 813,000 | $ 796,000 |
Noncurrent | $ 7,040,000 | $ 7,820,000 |
Weighted-average remaining lease term (years) | 13 years 3 months 18 days | |
Weighted-average discount rate | 4.30% |
Lease Liability (Details Narrat
Lease Liability (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended |
Mar. 31, 2022 | Sep. 30, 2023 | Sep. 30, 2023 | |
Cash paid for leases | $ 319,000 | $ 948,000 | |
Minimum [Member] | |||
Operating lease payment | $ 61,000 | ||
Maximum [Member] | |||
Operating lease payment | $ 78,000 |
Commitments and Contingencies (
Commitments and Contingencies (Details Narrative) - License Agreement [Member] - Bio Medical [Member] | Mar. 19, 2022 USD ($) |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |
Loss contingency allegations | In exchange, the Licensee shall pay the Company a royalty of 5.5% of net sales. Under the terms of the Equivir Agreement, the Company shall reimburse the Licensee for 50% of the development costs provided that the development costs shall not exceed $1,250,000. As of September 30, 2023 and December 31, 2022, no liability has been recorded in relation to the Equivir License as development of the Equivir technology has not begun and no reasonable amount can be estimated |
Research and development expense | $ 1,250,000 |
Stockholders_ Equity (Details N
Stockholders’ Equity (Details Narrative) - USD ($) | 9 Months Ended | |||||||||||||
Oct. 31, 2023 | Apr. 10, 2023 | May 25, 2022 | May 17, 2022 | May 05, 2022 | Mar. 10, 2022 | Mar. 09, 2022 | Feb. 28, 2022 | Feb. 28, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022 | Jun. 30, 2022 | Feb. 18, 2022 | |
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||
Number of shares of common stock, values | $ 268,000 | $ 17,405,000 | ||||||||||||
Stock issued during period shares acquisitions | 17,570,948 | |||||||||||||
Common stock shares, issued | 140,264,250 | 139,017,172 | ||||||||||||
Common stock shares, outstanding | 140,264,250 | 139,017,172 | ||||||||||||
Common Stock [Member] | ||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||
Number of shares of common stock | 1,247,000 | 47,924,000 | ||||||||||||
Number of shares of common stock, values | $ 25,000 | $ 858,000 | ||||||||||||
Subsequent Event [Member] | Common Stock [Member] | DSS Bio Health Securities Inc [Member] | Maximum [Member] | ||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||
Ownership percentage | 88% | |||||||||||||
Subsequent Event [Member] | Common Stock [Member] | DSS Bio Health Securities Inc [Member] | Minimum [Member] | ||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||
Ownership percentage | 12% | |||||||||||||
True Partners Capital Holdings Limited [Member] | ||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||
Stock issued during period shares acquisitions | 62,122,908 | |||||||||||||
Share price | $ 0.41 | |||||||||||||
Alset E Home International Inc [Member] | ||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||
Shares issued for convertible debt | 21,366,177 | |||||||||||||
Shares issued for convertible debt, value | $ 8,350,000 | |||||||||||||
Accrued unpaid interest | $ 367,000 | |||||||||||||
Impac tBio Medical [Member] | ||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||
Common stock shares, issued | 3,877,282,251 | 3,877,282,251 | 3,877,282,251 | |||||||||||
Common stock shares, outstanding | 3,877,282,251 | 3,877,282,251 | 3,877,282,251 | |||||||||||
Equity reserve stock split | 70,496,041 | |||||||||||||
Impac tBio Medical [Member] | Subsequent Event [Member] | ||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||
Equity reserve stock split | reverse stock split of 1 for 55. | |||||||||||||
Impac tBio Medical [Member] | Subsequent Event [Member] | Series A Convertible Preferred Stock [Member] | ||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||
Equity reserve stock split | 60,496,041 | |||||||||||||
Impac tBio Medical [Member] | Subsequent Event [Member] | Common Stock [Member] | ||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||
Equity reserve stock split | 60,496,041 | |||||||||||||
Stock Purchase Agreement [Member] | ||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||
Number of shares of common stock | 3,986,877 | 44,619,423 | ||||||||||||
Issued price per share | $ 0.3810 | $ 0.3810 | ||||||||||||
Number of shares of common stock, values | $ 1,519,000 | $ 17,000,000 | ||||||||||||
Stock Purchase Agreement [Member] | Alset E Home International Inc [Member] | ||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||
Number of shares of common stock | 3,986,877 | 44,619,423 | ||||||||||||
Issued price per share | $ 0.3810 | $ 0.3810 | ||||||||||||
Number of shares of common stock, values | $ 1,519,000 | $ 17,000,000 | ||||||||||||
Employment Agreement [Member] | Heng Fai Ambrose Chan [Member] | ||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||
Number of shares of common stock | 15,389,995 | 894,084 | ||||||||||||
Number of shares of common stock, values | $ 5,848,000 | $ 340,000 | ||||||||||||
Employment Agreement [Member] | Frank Heuszel [Member] | ||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||
Number of shares of common stock | 1,247,078 | 63,205 | ||||||||||||
Number of shares of common stock, values | $ 268,000 | $ 29,000 |
Schedule of Supplemental Cash F
Schedule of Supplemental Cash Flow Information (Details) - USD ($) | 9 Months Ended | |
Sep. 30, 2023 | Sep. 30, 2022 | |
Supplemental Cash Flow Elements [Abstract] | ||
Cash paid for interest | $ 3,432,000 | $ 1,907,000 |
Non-cash investing and financing activities: | ||
Notes receivable converted to equity investments | 1,940,000 | |
Shares issued for acquisition of marketable security | 7,169,000 | |
Shares issued for the acquisition of notes receivable | 8,717,000 | |
Right of use asset addition | 9,895,000 | |
Shares issued in lieu of bonus cash | $ 268,000 | $ 6,216,000 |
Schedule of Operations by Repor
Schedule of Operations by Reportable Segment (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Segment Reporting Information [Line Items] | ||||
Revenue | $ 4,182,000 | $ 11,862,000 | $ 23,245,000 | $ 35,927,000 |
Interest expense | 51,000 | 606,000 | 438,000 | 2,105,000 |
Interest income | 682,000 | 319,000 | 1,220,000 | 613,000 |
Net income (loss) from operations | (6,681,000) | (24,802,000) | (53,039,000) | (39,161,000) |
Capital expenditures | 67,000 | 373,000 | 679,000 | 1,349,000 |
Identifiable assets | 196,551,000 | 264,880,000 | 196,551,000 | 264,880,000 |
Depreciation and Amortization | 2,927,000 | 9,351,000 | ||
Stock based compensation | 319,000 | 4,000 | ||
Interest income | 1,220,000 | |||
Operating Segments [Member] | Product Packaging [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue | 3,378,000 | 4,707,000 | 13,038,000 | 11,876,000 |
Interest expense | 51,000 | 42,000 | 137,000 | 100,000 |
Interest income | ||||
Net income (loss) from operations | (579,000) | (1,077,000) | (88,000) | (755,000) |
Capital expenditures | 67,000 | 300,000 | 596,000 | 1,242,000 |
Identifiable assets | 21,554,000 | 24,035,000 | 21,554,000 | 24,035,000 |
Depreciation and Amortization | 168,000 | 525,000 | ||
Stock based compensation | 1,000 | |||
Interest income | ||||
Operating Segments [Member] | Commercial Banking [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue | 108,000 | 370,000 | 422,000 | 644,000 |
Interest expense | ||||
Interest income | ||||
Net income (loss) from operations | (24,000) | 221,000 | (1,800,000) | 638,000 |
Capital expenditures | ||||
Identifiable assets | 39,446,000 | 48,121,000 | 39,446,000 | 48,121,000 |
Depreciation and Amortization | ||||
Stock based compensation | ||||
Interest income | ||||
Operating Segments [Member] | Direct Marketing Online Sales [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue | 523,000 | 4,956,000 | 6,088,000 | 18,000,000 |
Interest expense | 193,000 | (6,000) | 193,000 | |
Interest income | 660,000 | |||
Net income (loss) from operations | (1,010,000) | (15,379,000) | (32,272,000) | (19,102,000) |
Capital expenditures | 73,000 | 88,000 | ||
Identifiable assets | 7,102,000 | 39,979,000 | 7,102,000 | 39,979,000 |
Depreciation and Amortization | 41,000 | 248,000 | ||
Stock based compensation | 3,000 | |||
Interest income | 945,000 | |||
Operating Segments [Member] | Biotechnology [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue | 94,000 | |||
Interest expense | ||||
Interest income | 6,000 | |||
Net income (loss) from operations | (1,151,000) | (909,000) | (5,933,000) | (2,198,000) |
Capital expenditures | 17,000 | |||
Identifiable assets | 49,816,000 | 57,225,000 | 49,816,000 | 57,225,000 |
Depreciation and Amortization | 278,000 | 835,000 | ||
Stock based compensation | 94,000 | |||
Interest income | 149,000 | |||
Operating Segments [Member] | Securities [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue | 173,000 | 1,646,000 | 3,697,000 | 4,817,000 |
Interest expense | 371,000 | 307,000 | 1,812,000 | |
Interest income | 16,000 | |||
Net income (loss) from operations | (2,166,000) | (3,182,000) | (8,606,000) | (8,334,000) |
Capital expenditures | 66,000 | 15,000 | ||
Identifiable assets | 69,498,000 | 81,766,000 | 69,498,000 | 81,766,000 |
Depreciation and Amortization | 2,423,000 | 7,637,000 | ||
Stock based compensation | 79,000 | |||
Interest income | 126,000 | |||
Operating Segments [Member] | Corporate Segment [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue | 183,000 | 496,000 | ||
Interest expense | ||||
Interest income | ||||
Net income (loss) from operations | (1,751,000) | (4,476,000) | (4,340,000) | (9,410,000) |
Capital expenditures | 4,000 | |||
Identifiable assets | $ 9,135,000 | 13,754,000 | 9,135,000 | 13,754,000 |
Depreciation and Amortization | 17,000 | 106,000 | ||
Stock based compensation | $ 143,000 | $ 3,000 | ||
Interest income |
Schedule of Disaggregation of R
Schedule of Disaggregation of Revenue (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Segment Reporting Information [Line Items] | ||||
Total Printed Products | $ 3,315,000 | $ 5,032,000 | $ 12,976,000 | $ 12,650,000 |
Direct Marketing | 523,000 | 4,937,000 | 6,088,000 | 17,939,000 |
Total Rental Income | 236,000 | 1,485,000 | 3,464,000 | 4,656,000 |
Total Net Investment Income | 108,000 | 370,000 | 422,000 | 644,000 |
Total Commission income | 295,000 | |||
Packaging Printing and Fabrication [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Total Printed Products | 3,293,000 | 4,888,000 | 12,539,000 | 12,357,000 |
Commercial and Security Printing [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Total Printed Products | 22,000 | 144,000 | 347,000 | 293,000 |
Direct Marketing Internet Sales [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Direct Marketing | 523,000 | 4,937,000 | 6,088,000 | 17,939,000 |
Rental Income [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Total Rental Income | 236,000 | 1,485,000 | 3,464,000 | 4,656,000 |
Net Investment Income [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Total Net Investment Income | 108,000 | 370,000 | 422,000 | 644,000 |
Commission Income [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Total Commission income | $ 295,000 |
Related Party Transactions (Det
Related Party Transactions (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||||||||||||||
Aug. 09, 2022 | May 17, 2022 | May 17, 2022 | Mar. 09, 2022 | Feb. 28, 2022 | Oct. 13, 2021 | Oct. 13, 2021 | Jul. 22, 2021 | Mar. 18, 2021 | Oct. 31, 2017 | Nov. 30, 2021 | Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | Mar. 16, 2021 | Mar. 02, 2020 | |
Unrealized gain on investment | $ (8,039,000) | $ (3,659,000) | |||||||||||||||||
Interest expense | $ 51,000 | $ 42,000 | 438,000 | $ 100,000 | |||||||||||||||
Purchase price | 268,000 | $ 17,405,000 | |||||||||||||||||
Stock issued for acquisition | 17,570,948 | ||||||||||||||||||
BMIC Loan [Member] | |||||||||||||||||||
Debt instrument, face amount | $ 3,000,000 | $ 3,000,000 | 512,000 | 512,000 | 3,000,000 | ||||||||||||||
Maturity date | Oct. 12, 2022 | Oct. 12, 2022 | |||||||||||||||||
Wilson Loan [Member] | |||||||||||||||||||
Debt instrument, face amount | $ 3,000,000 | $ 3,000,000 | $ 1,997,000 | 1,997,000 | 3,000,000 | ||||||||||||||
Maturity date | Oct. 12, 2022 | Oct. 12, 2022 | |||||||||||||||||
Stock Purchase Agreement [Member] | |||||||||||||||||||
Number of shares of common stock | 3,986,877 | 44,619,423 | |||||||||||||||||
Issued price per share | $ 0.3810 | ||||||||||||||||||
Purchase price | $ 1,519,000 | $ 17,000,000 | |||||||||||||||||
Impact Oncology PTE Ltd. [Member] | |||||||||||||||||||
Investment owned balance shares | 2,480,000 | ||||||||||||||||||
Consideration transferred | $ 2,480,000 | ||||||||||||||||||
Options to purchase additional shares | 250,000 | ||||||||||||||||||
Equity position percentage | 16% | 15.70% | |||||||||||||||||
Proceeds from stock options exercised | $ 1,000,000 | ||||||||||||||||||
Alset Note [Member] | |||||||||||||||||||
Debt instrument, face amount | $ 8,350,000 | $ 8,350,000 | $ 8,350,000 | 8,350,000 | |||||||||||||||
Debt instrument interest rate | 8% | ||||||||||||||||||
Debt instrument maturity date, description | matures in December 2023 | ||||||||||||||||||
Principal amount | $ 8,805,000 | 8,805,000 | |||||||||||||||||
Shares issued for convertible debt | 21,366,177 | ||||||||||||||||||
Accrued unpaid interest | $ 119,000 | 119,000 | 119,000 | ||||||||||||||||
Interest expense | $ 625,000 | $ 346,000 | |||||||||||||||||
Alset International Limited [Member] | |||||||||||||||||||
Investment owned balance shares | 127,179,291 | 127,179,291 | 127,179,291 | ||||||||||||||||
Warrants percentage | 4% | ||||||||||||||||||
Marketable securities | $ 3,726,000 | $ 3,726,000 | $ 3,319,000 | ||||||||||||||||
Unrealized gain on investment | $ 281,000 | ||||||||||||||||||
Unrealized loss on investment | $ 75,000 | ||||||||||||||||||
Shares issued for convertible debt | 21,366,177 | ||||||||||||||||||
American Medical REIT Inc. [Member] | |||||||||||||||||||
Debt instrument, face amount | $ 8,350,000 | $ 8,350,000 | |||||||||||||||||
Debt instrument interest rate | 1% | ||||||||||||||||||
Principal amount | $ 111,000 | ||||||||||||||||||
Unpaid interest | $ 367,000 | ||||||||||||||||||
American Medical REIT Inc. [Member] | Unsecured Promissory Note [Member] | |||||||||||||||||||
Debt instrument, face amount | $ 200,000 | ||||||||||||||||||
Debt instrument interest rate | 8% | ||||||||||||||||||
Exercise price of warrants | $ 5 | ||||||||||||||||||
Warrants and rights outstanding | $ 200,000 | ||||||||||||||||||
HWH International Inc [Member] | |||||||||||||||||||
Debt instrument, face amount | $ 50,000 | ||||||||||||||||||
Issued price per share | $ 0.15 | ||||||||||||||||||
Conversion of stock | 333,333 | ||||||||||||||||||
Warrants to purchase | 333,333 | ||||||||||||||||||
Cancelleation of warrants and notes | $ 78,635.62 | ||||||||||||||||||
True Partners Capital Holdings Limited [Member] | |||||||||||||||||||
Stock issued for acquisition | 62,122,908 | ||||||||||||||||||
Number of shares exchanged | 17,570,948 |
Subsequent Events (Details Narr
Subsequent Events (Details Narrative) - shares | 9 Months Ended | |||
Oct. 31, 2023 | Sep. 30, 2023 | Dec. 31, 2022 | Jun. 30, 2022 | |
Common stock shares, issued | 140,264,250 | 139,017,172 | ||
Common stock shares, outstanding | 140,264,250 | 139,017,172 | ||
Impac tBio Medical [Member] | ||||
Common stock shares, issued | 3,877,282,251 | 3,877,282,251 | 3,877,282,251 | |
Common stock shares, outstanding | 3,877,282,251 | 3,877,282,251 | 3,877,282,251 | |
Equity reserve stock split | 70,496,041 | |||
Subsequent Event [Member] | Common Stock [Member] | Maximum [Member] | Bio Medical [Member] | ||||
Ownership percentage | 88% | |||
Subsequent Event [Member] | Common Stock [Member] | Minimum [Member] | Bio Medical [Member] | ||||
Ownership percentage | 12% | |||
Subsequent Event [Member] | Impac tBio Medical [Member] | ||||
Equity reverse stock split | reverse stock split of 1 for 55. | |||
Subsequent Event [Member] | Impac tBio Medical [Member] | Series A Convertible Preferred Stock [Member] | ||||
Equity reserve stock split | 60,496,041 | |||
Subsequent Event [Member] | Impac tBio Medical [Member] | Common Stock [Member] | ||||
Equity reserve stock split | 60,496,041 |